

Oligosaccharide Analogues of Polysaccharides

Part 22¹⁾

Synthesis of Cyclodextrin Analogues Containing a Buta-1,3-diyne-1,4-diyl or a Butane-1,4-diyl Unit

by Barbara Hoffmann, Diana Zanini, Isabelle Ripoche, Roland Bürli, and Andrea Vasella*

Laboratorium für Organische Chemie, ETH-Zentrum, Universitätstrasse 16, CH-8092 Zürich

Dedicated to *Edgar Heilbronner* on the occasion of his 80th birthday

The peracetylated hexaamylose (maltohexaose) **18** was obtained by an improved acetolysis of cyclo-maltohexaose (α -cyclodextrin, α -CD, **16**), and transformed into the benzyl- and 4-chlorobenzyl-protected thioglycosides **22** and **23**, respectively (*Scheme 2*). Sequential chain elongation of **22** and **23** by glycosidation of the *C*-ethynylated glucosides **9** and **11** gave the α -anomeric heptaglycosides **24** and **26**, respectively, and their anomers **25** and **27** (*Scheme 3*). These were transformed into the glycosyl acceptors **28**, **30**, and **31**. Glycosidation of **28** and **30** by **13** and **15**, respectively, led to the benzyl-protected octasaccharides **32** ($\alpha\alpha_5\alpha$) and **33** ($\beta\alpha_5\alpha$), and to the chlorobenzylated analogues **34** ($\alpha\alpha_5\alpha$) and **35** ($\beta\alpha_5\alpha$), while glycosidation of **31** led to the 4-chlorobenzyl-protected analogues **36** ($\alpha\alpha_5\beta$) and **37** ($\beta\alpha_5\beta$) (*Scheme 4*). *Hay* coupling of *O*-Bn- and *O*-Ac-protected linear octaoses **32** ($\alpha\alpha_5\alpha$) and **33** ($\beta\alpha_5\alpha$) led to the cyclooctaamylose (γ -cyclodextrin) analogues **38** and **43**, respectively (*Scheme 5*). Similarly, the 4-chlorobenzyl-protected analogues **34** and **35** gave **39** and **44**, and the anomeric linear precursors **36** and **37** provided the cyclooctaamylose analogues **48** and **50**, respectively (*Scheme 6*). The influence of the constitution and configuration of the linear precursors on the rate and yield of the cyclisation was relatively weak. Deprotection and hydrogenation of **38** and **43** yielded the γ -CD analogues **42** ($\alpha\alpha_5\alpha$) and **47** ($\beta\alpha_5\alpha$), where one glycosidic O-atom is replaced by a butanediyl group, while FeCl_3 -promoted dechlorobenzylation of **39** and **44** did not affect the butadiyne moiety and afforded the acetyleno γ -CD's **40** ($\alpha\alpha_5\alpha$) and **45** ($\beta\alpha_5\alpha$), respectively. Similarly, deprotection of **48** and **50** afforded the acetyleno γ -CD analogues **49** ($\alpha\alpha_5\beta$) and **51** ($\beta\alpha_5\beta$), respectively, which contain one butanediyl moiety instead of a glycosidic O-atom. MM3* Force-field calculations evidence the strong influence of the configuration and constitution of the new γ -CD analogues on the shape of the cavity.

Introduction and Plan. – Cyclodextrins (CDs, cycloamyloses) have commanded interest as catalysts [2][3], drug delivery systems [3–5], ligands [6], constituents of chiral separation media [7] and monolayers [8], and, particularly, as host molecules forming inclusion complexes [5][6][9]. The size and shape of the cavity of CDs plays an essential role in the formation of these inclusion complexes, with hydrophobic interactions, H-bonding, *Van der Waals* forces, and the reduction of conformational strain contributing to their stability [10–13]. There is strong interest in modifying the size and shape of the cavity, either by single or multiple substitution [14], capping [15], and changing the configuration [16], or by combining structural elements of CDs with noncarbohydrate moieties, as in the glycophanes [17], glyco-crown ethers [18], and cyclic acetylenosaccharides [19–21]. The known cyclic acetylenosaccharides result from

¹⁾ Part 21: see [1].

combinations of glucose-1,4-diyl and buta-1,3-diyne-1,4-diyl residues [19][20], or from a ternary combination of glucose-1,4-diyl, buta-1,3-diyne-1,4-diyl, and 2,2'-dipyridinyl moieties [21]. In these acetylenosaccharides, all glycosidic O-atoms are replaced by buta-1,3-diyne-1,4-diyl groups. Thus, they cover an extreme point in the process of a progressive formal replacement of the glycosidic O-atom by buta-1,3-diyne-1,4-diyl moieties. We intended to synthesise CD analogues in which only one of the α -(1 \rightarrow 4)-*O*-glycosidic linkages is replaced by a buta-1,3-diyne-1,4-diyl unit. Its incorporation will interrupt the cyclic H-bond network [22] of the related CD and diminish its rigidity that should be diminished further by reduction of the butadiyne to a butane-1,4-diyl moiety.


We planned to prepare a γ -CD analogue by *Hay* coupling of a linear 1, ω -diethynylated maltooctaose. The maltooctaose should be available by double glycosylation, first with a protected maltohexaose as glycosyl donor and then by glycosylation of the resulting maltoheptaose using a C(4)-ethynylated glucosyl donor. Maltohexaose should be derived from cyclomaltohexaose (α -CD) by known acetolytic ring cleavage [23], while the glucosyl donor and acceptor carrying an ethynyl group either at C(4) or at C(1) should be available from anhydroglucose **1** following established routes [19][24][25]. We intended to use *O*-Bn substituents as permanent protecting groups and to compare the resulting benzyl ethers to their 4-chlorobenzyl analogues that might crystallize more readily and be cleaved under milder conditions [26][27].

Results and Discussion. – The glucosyl acceptors **9** and **11** were prepared similarly to the known 1,4-diethynylated analogues [24][28], *i.e.*, by intramolecular invertive ring opening of an appropriate (ethynyl)silyl ether of 1,6-anhydroglucose (**1**) (*Scheme 1*). It proved advantageous to transform **1** into the bis-silyl ether **3**, using the chloro(ethynyl)silane **2**. The bis-silyl ether **3** was obtained in 82% yield and treated first with *in situ* generated $\text{BuAlCl}_2 \cdot \text{LiCl}$ and lutidine in toluene and then with 0.1M HCl in MeOH to remove any remaining SiO groups. The resulting crude C(1)-alkynylated tetraol **5** was purified *via* the acetate **4**, isolated in 50–55% yield, and benzylidenated. The resulting benzylidene acetal **6** was benzylated to **7** (97%), and 4-chlorobenzylated to **8** (86%). Reductive opening of the dioxane ring of **7** yielded the desired monomer **9** (84%), while **8** was debenzylidenated to **10** with I_2 in MeOH [29] (71%). The diol **10** was treated with $(\text{Bu}_3\text{Sn})_2\text{O}$ [30] and 4-chlorobenzylated at O–C(6) to give **11** (75%).

Taking previous glycosidations with ethynylated glucosyl donors into account [28], we prepared the thioglycosides **13** and **15** as glucosyl donors; the former from the known glucosyl chloride **12** [24] under conditions of phase-transfer catalysis [31], and the latter by chlorobenzilation of the known thioglycoside **14** [25]. The different protecting groups of **13** were chosen to facilitate the separation of isomers at the octasaccharide stage; a combination of protecting groups had proven advantageous in the synthesis of linear acetylenosaccharides [32].

For the synthesis of maltohexaose, we acetolytically cleaved per-*O*-acetylated α -CD **17** [33], similarly as described by *Sakairi et al.* [23], but with Ac_2O and 70% HClO_4 at 0° (*Scheme 2*). This modified procedure yielded 95% of the fully acetylated hexamalto-saccharide **18** ($\alpha/\beta > 9:1$) after recrystallisation in EtOH, as compared to a yield of 41–52%, resulting from a cleavage with Ac_2O and H_2SO_4 at 50–60° [23]. The

Scheme 1




a) 2,6-Dimethylpyridine, $\text{Cl}(\text{CH}_2)_2\text{Cl}$; 82%. b) $\text{AlCl}_3, \text{BuLi}, 2,6\text{-dimethylpyridine}, \text{toluene}, 85 \rightarrow 100^\circ; 0.1\text{M HCl/MeOH}; \text{Ac}_2\text{O}, \text{pyridine}; 53\%$. c) $0.1\text{M HCl/EtOH}; 96\%$. d) $\alpha, \alpha\text{-Dimethoxytoluene}, \text{TsOH} \cdot \text{H}_2\text{O}; 84\%$. e) $\text{BnBr}, \text{NaH}, \text{DMF}; 97\%$. f) $4\text{-Cl-C}_6\text{H}_4\text{CH}_2\text{Cl}, \text{Bu}_4\text{NI}, \text{NaH}, \text{DMF}; 86\%$. g) $\text{NaBH}_3\text{CN}, 1\text{M HCl in Et}_2\text{O}, 3\text{-\AA molecular sieves}, \text{THF}; 84\%$. h) $1\% \text{I}_2/\text{MeOH}, \text{reflux}; 71\%$. i) $4\text{-Cl-C}_6\text{H}_4\text{CH}_2\text{Cl}, \text{Bu}_4\text{NI}, (\text{Bu}_3\text{Sn})_2\text{O}, \text{toluene}; 75\%$. j) $\text{PhSH}, \text{Bu}_4\text{NSH}, \text{AcOEt}; 50\%$. k) $4\text{-Cl-C}_6\text{H}_4\text{CH}_2\text{Cl}, \text{Bu}_4\text{NI}, \text{NaH}, \text{DMF}; 90\%$.

hexasaccharide **18** was converted to the phenyl thioglycoside **19** (85%) according to *Hanessian's* method [34]. Deacetylation of **19** yielded 94% of the hexasaccharide **20**. The 4^{VI},6^{VI}-*O*-benzylidene acetal **21** was best prepared with α, α -dibromotoluene in pyridine according to the method of *Garegg* and *Swahn* [35]; the acetal exchange method of *Evans* proved less satisfactory [36] (see also [23]). Partially purified **21** was, on the one hand, benzylated to the hexasaccharide thioglycoside **22** (78% from **20**) and, on the other hand, 4-chlorobenzylated to **23** (78% from **20**).

The Bn-protected acceptor **9** was glycosylated with the benzylated hexasaccharide donor **22** under standard conditions (NIS, TfOH, Et₂O) to yield 86% of the anomeric

Scheme 2




a) Ac₂O/pyridine; (quant.). *b)* 70% aq. HClO₄, Ac₂O, 0 → 23°; 95%. *c)* ZnI₂, Me₃SiSPh, CH₂Cl₂; 85%. *d)* 1M NaOMe in MeOH; 94%. *e)* α,α-Dibromotoluene, pyridine. *f)* NaH, BnBr, Et₄NI, imidazole, DMF; 78% from **20**. *g)* 4-Cl-C₆H₄CH₂Cl, Bu₄NI, NaH, DMF; 80% from **20**.

heptasaccharides **24** ($\alpha_5\alpha$)²) and **25** ($\alpha_5\beta$) in a ratio of 3 : 1 (Scheme 3). Similarly, the chlorobenzyl-protected acceptor **11** was glycosylated with the chlorobenzylated donor **23** to yield 95% of the anomeric heptasaccharides **26** ($\alpha_5\alpha$) and **27** ($\alpha_5\beta$) in a ratio of 5 : 4. The mixtures **24/25** and **26/27** were readily separated by flash chromatography. Cleavage of the dioxane ring of the fully α -D-configured benzylated **24** with Me₃N · BH₃ and AlCl₃ in THF [37] yielded 75% of the alcohol **28**. Similarly to the monomeric benzylidene acetal **8**, the major $\alpha_5\alpha$ -configured heptasaccharide **26** was debenzylidened to afford 60% of the diol **29** that was regioselectively 4-chlorobenzylated *via* a tin alkoxide to yield 67% of **30**. The dioxane ring of the minor, 4-chlorobenzylated $\alpha_5\beta$ -heptasaccharide **27** was reductively cleaved with Et₃SiH and BF₃ · OEt₂ [38] to yield 76% of the alcohol **31**.

Glycosidation of the Bn-protected heptasaccharide **28** with **13** under standard conditions yielded 68% of the anomeric octasaccharides **32** ($\alpha\alpha_5\alpha$), and **33** ($\beta\alpha_5\alpha$) in a ratio of 5 : 2 (Scheme 4). These anomers were separated by flash chromatography, and their structure was determined by ¹H- and ¹³C-NMR spectroscopy. Similarly, the 4-chlorobenzylated heptasaccharide **30** and the donor **15** afforded the anomeric octasaccharides **34** ($\alpha\alpha_5\alpha$) and **35** ($\beta\alpha_5\alpha$) that were isolated in 48 and 36% yield, respectively, after a tedious separation.

²⁾ To readily identify the glycosides, we specify the configuration of the new glycosidic centers relative to the conserved ones of the hexamaltoside moiety.

Scheme 3




a) NIS (*N*-Iodosuccinimide), TfOH (trifluoromethanesulfonic acid), 3-Å molecular sieves, Et₂O, -60°; **24/25** 3:1 (86%); **26/27** 5:4 (95%). b) Me₃N·BH₃, AlCl₃, 3-Å molecular sieves, THF; 75%. c) 1% I₂/MeOH, reflux; 60%. d) 4-Cl-C₆H₄CH₂Cl, Bu₄NI, (Bu₃Sn)₂O, toluene, 90°, 67%. e) BF₃·OEt₂, Et₃SiH, CH₂Cl₂; 76%.

Finally, glycosidation of the $\alpha_5\beta$ -configured heptasaccharide **31** with **15** yielded 86% of the anomeric octasaccharides **36** ($\alpha\alpha_5\beta$) and **37** ($\beta\alpha_5\beta$) in a ratio of 5:4.

In the ¹H-NMR spectrum of **24**, the six anomeric H-atoms resonate at 5.68, 5.66, 5.64, 5.62, 5.60, and 5.54 ppm as *d*'s with coupling constants in the range of 3.5 Hz. The ¹H-NMR spectrum of **26** shows four *d* (5.52 (1 H), 5.51 (1 H), 5.48 (3 H), and 5.44 (1 H) ppm) for the six anomeric H-atoms, while the ¹H-NMR spectra of **25** and **27** only exhibit signals of five α -anomeric H-atoms. The H-C(1) signal of the β -D-linked moiety is

Scheme 4



a) NIS, TlOH, 3-Å molecular sieves, toluene, -60° ; **32/33** 5:2 (68%); **34/35** 5:4 (84%); **36/37** 1:1 (86%).

hidden. The α -anomeric C(1^{III-VI}) of **25** and **27** resonate at 97.46, 96.74, 96.42, 96.22, and 96.12, and at 97.82, 96.86, 96.62 (2 C), and 96.44 ppm, respectively, and the β -anomeric C(1^{II}) at 102.15 and 102.20 ppm, respectively. The acetylenic H-atom gives rise to a *d* ($J=2.3$ Hz) at 2.64 and 2.57 ppm for **24** and **25**, and at 2.68 and 2.64 for **27** and **26**, respectively. The ¹H-NMR spectrum of **29** shows a *d* at 2.39 ppm ($J=2.3$ Hz) for HO-C(4^{VII}) and a *t* at 1.8 ppm ($J=6.5$ Hz) for HO-C(6^{VII}), whereas the ¹H-NMR spectrum of **30** displays only a *d* at 2.55 ppm ($J=2.4$ Hz) for HO-C(4^{VII}). The ¹H-NMR spectra of **32** and **33** show a signal at 2.18 ppm ($J=2.3$ Hz), corresponding to a second acetylenic H-atom. Signals of H_α-C(1^{II-VIII}) are visible in the spectrum of **32** and signals of H_α-C(1^{III-VIII}) in the spectrum of **33**. The ¹³C-NMR spectrum of **33** confirms the anomeric configuration showing a *d* at 102.27 ppm for C(2^{VII}). The ¹H-NMR spectrum of **34** shows a new *d* at 2.17 ppm ($J=2.3$ Hz) corresponding to an acetylenic H-atom, confirming the incorporation of an alkyne moiety. Five other diagnostic signals at 5.57 (*d*, $J=3.5$), 5.55 (*m*, 3 H), 5.50 (*d*, $J=3.5$), 5.48 (*d*, $J=3.7$), and 5.46 (*d*, $J=3.5$) ppm correspond to the seven equatorial anomeric H-atoms of the α -(1 \rightarrow 4)-*O*-glycosidic linkages. For **35**, the β -D-configuration of C(1^{VIII}) is revealed by the characteristic *d* of H-C(1^{VIII}) at 4.22 ppm ($J=8.0$ Hz), whereas the α -D-configured centers give rise to five *d* (5.66 (1 H), 5.52 (2 H), 5.48 (1 H), 5.48 (1 H), and 5.43 (1 H) ppm) with coupling constants of *ca.* 3.5 Hz for the six equatorial anomeric H-C(1^{II-VII}). In addition, the ¹³C-NMR spectrum of **35** shows the signal for the β anomeric C(1^{VIII}) at 102.32 ppm.

Upon treatment with excess $\text{Cu}(\text{OAc})_2$ in dilute solution ($4.6 \mu\text{M}$ in $\text{MeCN}/\text{pyridine}$ 3:1 [39]), the octasaccharides **32**, **33**, **34**, **35**, **36**, and **37** cyclised smoothly to the 1,3-butadiynediyl-saccharides **38**, **43**, **39**, **44**, **48**, and **50**, respectively. The ($\alpha_5\alpha$)-octasaccharides **32** and **34** cyclised most rapidly, and the ($\alpha_5\beta$)-isomer **36** most slowly, although the time required to complete the reaction did not differ by much (3 vs. 5 h). Yields ranged from 40 to 60%. Cyclisation was readily ascertained by the disappearance of the acetylenic signals in the $^1\text{H-NMR}$ spectrum of the products. There was no obvious difference in the physicochemical properties of the Bn or 4-chlorobenzyl-protected intermediates and CD analogues. However, the easier removal of the 4-chlorobenzyl group by *Lewis* acids proved an advantage.

Hydrogenation of **38** and **43** in the presence of $\text{Pd}(\text{OH})_2$ in 2-methoxyethanol removed the Bn groups and reduced the butadiyne moiety, leading to the monoacetates **41** (99%) and **46** (96%), respectively (*Scheme 5*). Their de-*O*-acetylation gave the desired butano-CDs **42** and **47** in high yields. The 4-chlorobenzylated butadiynes **39**, **44**, **48**, and **50** were deprotected with FeCl_3 in CH_2Cl_2 , leading in 75–80% to the butadiynes **40**, **45**, **49**, and **51**, respectively (*Schemes 5 and 6*).

In (D_6)DMSO, $\text{HO-C}(2)$ of α - and β -CD resonates as a *d* at 5.48 and 5.70 ppm with $J(\text{H},\text{OH}) \approx 6.5$ Hz and $\text{HO-C}(3)$ as a *d* at 5.40 and 5.65 ppm with $J(\text{H},\text{OH}) \approx 2.3$ Hz, respectively. The coupling constants $J(2,\text{OH})$ and $J(3,\text{OH})$ are similar to those of maltobioses ($J(2',\text{OH}) = 6.2\text{--}6.3$ Hz, $J(3,\text{OH}) = 3.2$ Hz [40]) and indicate a *ca.* 1:1 flip-flop equilibrium between the $\text{O}(3)\text{--H}\cdots\text{O}(2')\text{--H}$ and the $\text{O}(2')\text{--H}\cdots\text{O}(3)\text{--H}$ H-bonded species (see also [22]). In γ -CD, $\text{HO-C}(2)$ and $\text{HO-C}(3)$ appear at 5.73 ppm as a broad signal. The interruption of the H-bond network in the new CD analogues is visible in the $^1\text{H-NMR}$ spectra in (D_6)DMSO of the butano-CD's **42** ($\alpha_5\alpha$) and **47** ($\beta_5\alpha$). The 300-MHz $^1\text{H-NMR}$ spectrum of **42** shows a broad signal at 5.84–5.36 ppm integrating for 13–14 OH and an OH *d* at 4.71 ppm ($J = 4.8$ Hz). One or possibly two OH signals are hidden below the $\text{H-C}(1)$ signals. The upfield shift of two OH signals suggests that $\text{HO-C}(5')$ (at 4.71 ppm) and $\text{HO-C}(3^{\text{VIII}})$, both vicinal to a butane-1,4-diyl group, are more or less completely solvated, and that the inter-residue flip-flop H-bonds for the seven maltobiosyl units are maintained. The 500-MHz $^1\text{H-NMR}$ spectrum of **47** shows signals for 12 OH groups at 5.8–5.38 ppm and 4 OH *d*'s at higher field (at 5.06, 4.97, 4.925, and 4.78 ppm) with $J(\text{H},\text{OH})$ of 4.7, *ca.* 2.5, 5.0, and 5.8 Hz, respectively. According to a $^1\text{H},^1\text{H-COSY}$ spectrum, the signals at 5.06 and 4.78 ppm belong to $\text{HO-C}(2^{\text{VIII}})$, and $\text{HO-C}(3^{\text{VIII}})$. Signal overlapping prevents an unambiguous assignment of the other OH signals. The comparison with **42** suggests that the signal at 4.925 ppm belongs to $\text{HO-C}(5')$. The small $J(\text{H},\text{OH})$ value (*ca.* 2.5 Hz) of the signal at 4.97 ppm may reveal a completely persistent H-bond of $\text{HO-C}(3^{\text{VII}})$ to $\text{OC}(5^{\text{VIII}})$ as it is observed in cellobiosyl units ($J(3,\text{OH}) \approx 2$ Hz [40]). The coupling constants of the other 3 OH groups resonating at higher field indicate more or less completely solvated OH groups. The 6 inter-residue flip-flop H-bonds of **47** are evidenced by the downfield shift for 12 OH at 5.8–5.38 ppm.

Possible ring conformations of the γ -CD analogues **40**, **42**, **45**, **47**, **49**, and **51** were obtained by molecular modeling (Macromodel V. 7.0 with a modified MM3* force field, gas phase [41]). The conformer of γ -CD possessing $\text{O}(2')\text{--H}\cdots\text{O}(3)\text{--H}$ interresidue H-bonds was used a starting structure. The $\text{O}(2')\text{--H}\cdots\text{O}(3)\text{--H}$ interresidue H-bonds of the maltosyl units and the preset $\text{O}(3)\text{--H}\cdots\text{O}(5')$ interresidue H-bond for the cellobiosyl unit were kept during the optimisation³). The minimal-energy conformations of **40**, **42**, **45**, **47**, **49**, and **51** lack any strong ring strain but indicate significantly different shapes (*Fig*). The CD analogues **40** and **42** ($\alpha_5\alpha$) possess a cavity in the form of a flattened circle. The cavity of **47** ($\beta_5\alpha$) is slightly elliptical, the one of **45** ($\beta_5\alpha$)

³) For geometric reasons, no $\text{O}(3)\text{--H}\cdots\text{O}(5')$ interresidue H-bonds are tolerated in the $\alpha_5\beta$ -configured **49** and only one (set between the units 7 and 8) in the $\beta_5\beta$ -configured **51**.





Figure. *MM3**-Calculated structures of the γ -CD-analogues 40, 42, 45, 47, 49, and 51. Numbers in the formulae give the maximal and the minimal distances between heavy atoms [\AA].


Scheme 5



a) Cu(OAc)₂, MeCN, pyridine, 80°; **38** (50%), **39** (60%), **43** (60%), **44** (56%). b) FeCl₃, CH₂Cl₂; **40** (73%), **45** (75%). c) H₂, Pd(OH)₂, MeOCH₂CH₂OH; **41** (quant.), **46** (89%). d) 1M NaOMe in MeOH; **42** (97%), **47** (quant.).

more strongly so, and the cavity of **49** ($\alpha\alpha_5\beta$) and **51** ($\beta\alpha_5\beta$) are clearly irregular, showing that both the position and the number of β -D-configured glycosidic centers have a strong impact on the shape of the cavity.

Scheme 6



a) Cu(OAc)₂, MeCN, pyridine, 80°; **48** (40%), **50** (45%). b) FeCl₃, CH₂Cl₂; **49** (78%), **51** (71%).

We thank the *Swiss National Science Foundation* and *F. Hoffmann-La Roche*, Basel, for generous support, Mrs. *B. Brandenberg* for measuring the 500-MHz NMR spectra, and Dr. *B. Bernet* for the help in the interpretation of the spectroscopic data and for checking the manuscript.

Experimental Part

General. Solvents were distilled before use: Et₂O, THF, and toluene from Na and benzophenone, CH₂Cl₂ from P₂O₅, DMF from CaSO₄, pyridine from KOH, and MeOH from CaH₂. Trifluoromethanesulfonic acid (TfOH) was distilled prior to use. *N*-Iodosuccinimide (NIS) and AlCl₃ were sublimed prior to use. NaH (55–65% on free-flowing powder moistened with oil) was washed with hexane. Qual. TLC: precoated silica-gel plates (*Merck* silica gel 60 *F*₂₅₄). Flash chromatography (FC): silica gel *Fluka* 60 (0.04–0.063 mm), silica H *Fluka* (5–40 μm). M.p.'s uncorrected. Optical rotations: 1-dm cell at 25°, 589 nm. FT-IR spectra: ca. 2% soln. in CHCl₃ (or in the indicated solvent). ¹H- and ¹³C-NMR spectra: 300 or 500 MHz, and 75 or 125 MHz, respectively. The assignment of ¹³C-NMR *multiplets* is based on DEPT spectra; due to the characteristic *J*(C,H) coupling, C≡CH appears in the DEPT spectrum as a very weak positive signal, whereas C≡CH gives no DEPT signal both these signal were assigned as *s*; see also [42]. MS: chemical ionisation (CI) with NH₃, fast-atom bombardment (FAB), or matrix-assisted laser-desorption ionisation mass spectrometry (MALDI-MS).

1,6-Anhydro-2,4-bis-O-[diethyl[2-(trimethylsilyl)ethynylsilyl]-β-D-glucopyranose (3). A suspension of **1** (35.7 g, 0.22 mol) in 1,2-dichloroethane (380 ml) was treated with 2,6-lutidine (105 ml, 0.904 mol) at 23°, stirred for 1.5 h, treated dropwise with **2** (100 g, 0.458 mol) over a period of 2 h, and stirred at 23° for 30 min. The mixture was diluted with CHCl₃ (500 ml) and washed with H₂O (250 ml). The aq. layer was extracted twice with CHCl₃ (2 × 250 ml). The combined org. fractions were washed with brine (100 ml), dried (MgSO₄), and evaporated. FC (hexane/AcOEt 20:1 → 10:1) gave **3** (103 g, 82%). White solid. *R*_f (hexane/AcOEt 3:1) 0.68. M.p. 45–46°. IR (CHCl₃): 3540w (br.), 2962s, 2900m, 2878m, ca. 2100w, 1459m, 1411m, 1108s (br.), 1076s (br.), 1008m, 972m, 896m. ¹H-NMR (300 MHz, CDCl₃): 5.36 (br. *s*, H–C(1)); 4.52 (br. *d*, *J* = 5.1, H–C(5)); 3.91

($d, J = 7.3, H_{endo}-C(6)$); 3.75–3.60 ($m, H-C(2), H-C(3), H-C(4), H_{exo}-C(6)$); 2.45 ($d, J = 5.0, HO-C(3)$); 1.08–1.00 ($m, 2 (MeCH_2)_2Si$); 0.78–0.62 ($m, 2 (MeCH_2)_2Si$); 0.18 ($s, 2 Me_3Si$). $^{13}C-NMR$ (75 MHz, $CDCl_3$): 116.72, 116.59, 109.26, 109.17 (4s, 2 $SiC\equiv CSi$); 103.33 ($d, C(1)$); 77.98 (2d); 75.27 (2d); 66.73 ($t, C(6)$); 6.47 ($q, 2 (MeCH_2)_2Si$); 6.31 ($t, 2 (MeCH_2)_2Si$); –0.25 ($q, 2 Me_3Si$). CI-MS: 544 (100, $[M + NH_4]^+$).

1,3,4,5-Tetra-O-acetyl-2,6-anhydro-7,8-dideoxy-8-C-(trimethylsilyl)-D-glycero-L-gulo-oct-7-ynitol (4). Under Ar, a suspension of freshly sublimed $AlCl_3$ (91.0 g, 0.684 mol) in toluene (1500 ml) was cooled to 0°, treated with 1.6M BuLi (428 ml, 0.684 mol), warmed to 23°, stirred for 30 min, heated to 80°, treated with a soln. of **3** (80.0 g, 0.152 mol) and 2,6-lutidine (35.5 ml, 0.304 mol) in toluene (800 ml) over a period of 15 min, stirred at 85° for 3.5 h and at 100° for 1 h, and allowed to cool to 23°. After evaporation, the residue was dissolved in 0.1M HCl in MeOH (1500 ml) and stirred for 10 h at 40°. The soln. was evaporated and co-evaporated twice with toluene. The residue was dissolved in pyridine (2080 ml), treated with Ac_2O (1300 ml), and stirred at 23° for 3 h. After evaporation, the residue was dissolved in AcOEt (500 ml) and washed with H_2O (500 ml). The aq. layer was extracted with AcOEt (2×250 ml). The combined org. layers were dried ($MgSO_4$) and evaporated. FC (hexane/AcOEt 10:1 → 5:1) gave **4** (34.6 g, 53%). White solid. R_f (hexane/AcOEt 1:1) 0.50. M.p. 113–114°. $[\alpha]_D^{25} = +151.1$ ($c = 0.51, CHCl_3$). IR ($CHCl_3$): 2962w, 2901w, 1751s, 1602w, 1430w, 1368m, 1068m, 1039m, 984w, 847m. ^1H-NMR (300 MHz, $CDCl_3$): 5.48 (br. dd, $J = 9.6, 10.0, H-C(4)$); 5.03 ($d, J = 5.8, H-C(6)$); 5.03 (br. dd, $J = 9.6, 10.0, H-C(3)$); 4.90 (dd, $J = 6.2, 10.0, H-C(5)$); 4.36–4.18 ($m, 2 H-C(1), H-C(2)$); 2.10, 2.08, 2.05, 2.03 (4s, 4 AcO); 0.24 (s, Me_3Si). $^{13}C-NMR$ (75 MHz, $CDCl_3$): 170.93, 170.33, 170.14, 169.88 (4s, 4 C=O); 97.64, 97.10 (2s, $C\equiv C$); 71.10, 70.75, 69.80, 68.37 (4d, C(2), C(3), C(4), C(5)); 65.93 ($d, C(6)$); 61.96 ($t, C(1)$); 20.73 ($q, 2 Me$); 20.63 ($q, 2 Me$); –0.32 (q, Me_3Si). CI-MS: 446 (100, $[M + NH_4]^+$), 429 (42, $[M + 1]^+$). Anal. calc. for $C_{19}H_{28}O_9Si$ (428.51): C 53.26, H 6.59; found: C 53.31, H 6.33.

2,6-Anhydro-7,8-dideoxy-8-C-(trimethylsilyl)-D-glycero-L-gulo-oct-7-ynitol (5). A soln. of **4** (33.5 g, 0.078 mol) in 0.1M HCl in EtOH (3000 ml) was stirred at 90° for 4 h. Evaporation and FC ($CH_2Cl_2/MeOH$ 5:1) gave **5** (19.5 g, 96%). Off-white solid. R_f ($CH_2Cl_2/MeOH$ 5:1) 0.23. M.p. 173–175°. IR (KBr): 3550–3290s, 2960m, 2905m, 2179w, 1386m, 1344m, 1252s, 1135m, 1108s, 1091s, 1057s, 1016s, 906m, 842s, 760m. ^1H-NMR (200 MHz, CD_3OD): 4.64 ($d, J = 5.8, H-C(6)$); 3.86–3.56 ($m, 2 H-C(1), H-C(2), H-C(4)$); 3.46 (dd, $J = 5.8, 9.6, H-C(5)$); 3.30 (br. t, $J = 9.2, H-C(3)$); 0.17 (s, Me_3Si). $^{13}C-NMR$ (75 MHz, CD_3OD): 102.33 ($s, C\equiv CSi$); 95.10 ($s, C\equiv CSi$); 76.97, 76.25, 72.36, 71.81, (4d, C(2), C(3), C(4), C(5)); 70.42 ($d, C(6)$); 62.95 ($t, C(1)$); –0.07 (q, Me_3Si). CI-MS: 278 (100, $[M + NH_4]^+$), 260 (2, M^+). Anal. calc. for $C_{11}H_{20}O_5Si$ (260.36): C 50.75, H 7.74; found: C 50.71, H 7.36.

2,6-Anhydro-(R)-1,3-O-benzylidene-7,8-dideoxy-8-C-(trimethylsilyl)-D-glycero-L-gulo-oct-7-ynitol (6). A soln. of **5** (9.56 g, 36.9 mmol) in MeCN (210 ml) was treated with α, α -dimethoxytoluene (7.00 ml, 47.9 mmol) and TsOH · H_2O (200 mg), stirred at 23° for 10 min and at 70° for 2 h (MeOH is distilled off). The soln. was allowed to cool to 23°, treated with Et_3N (3 ml), and evaporated. FC (toluene/AcOEt 1:0 → 2:1) gave **6** (11.2 g, 84%). White solid. R_f (toluene/AcOEt 2:1) 0.27. M.p. 128–129°. IR ($CHCl_3$): 3594m, 3386w (br.), 3066w, 3007m, 2962m, 2871m, 2169w, 1457m, 1378m, 1331m, 1294m, 1107s, 1073s, 1035s, 993s, 917s, 886s, 848s. ^1H-NMR (200 MHz, $CDCl_3$): 7.54–7.50 ($m, 2$ arom. H); 7.41–7.36 ($m, 3$ arom. H); 5.53 ($s, PhCH$); 4.79 ($d, J = 4.6, H-C(6)$); 4.34 (dd, $J = 4.7, 10.3, H_{eq}-C(1)$); 4.03–3.89 ($m, H-C(2), H-C(4)$); 3.67–3.74 ($m, H-C(5), H_{ax}-C(1)$); 3.44 (br. t, $J \approx 9.3, H-C(3)$); 2.98 (br. s, $HO-C(4)$); 2.44 ($d, J = 7.2, HO-C(5)$); 0.22 (s, Me_3Si). $^{13}C-NMR$ (75 MHz, $CDCl_3$): 137.21 (s); 129.55 (d); 128.63 (2d); 126.48 (2d); 102.07 ($d, PhCH$); 98.80 ($s, C\equiv CSi$); 96.89 ($s, C\equiv CSi$); 81.21 ($d, C(3)$); 72.69, 71.55 (2d, C(4), C(5)); 69.50 ($d, C(2)$); 69.05 ($t, C(1)$); 65.89 ($d, C(6)$); –0.15 (q, Me_3Si). CI-MS: 349 (100, $[M + 1]^+$).

2,6-Anhydro-4,5-di-O-benzyl-1,3-O-benzylidene-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (7). Under Ar, a soln. of **6** (9.70 g, 27.8 mmol) in DMF (100 ml) was cooled to 0°, treated with NaH (1.40 g, 58.4 mmol), stirred for 15 min, treated with BnBr (7.94 ml, 69.5 mmol), stirred at 0° for 1 h, treated dropwise with MeOH (25 ml), and diluted with H_2O (100 ml) and $CHCl_3$ (100 ml). The org. and aq. phases were separated, and the aq. phase was extracted with $CHCl_3$ (2×150 ml). The combined org. layers were washed with brine (80 ml), dried ($MgSO_4$), and evaporated. FC (hexane/ Et_2O 10:1 → 1:1) gave **7** (13.3 g, 97%). White foam. R_f (hexane/ Et_2O 3:1) 0.32. M.p. 101–102°. $[\alpha]_D^{25} = +11.9$ ($c = 1.84, CHCl_3$). IR ($CHCl_3$): 3305m, 3167w, 3007m, 2908m, 2869w, 2118w, 1602w, 1497w, 1454m, 1368m, 1339w, 1314w, 1280w, 1174w, 1092s, 1029m, 988m, 913w. ^1H-NMR (200 MHz, $CDCl_3$): 7.55–7.26 ($m, 15$ arom. H); 5.60 ($s, PhCH$); 5.01–4.74 ($m, 2 ArCH$); 4.74 (dd, $J = 2.1, 5.8, H-C(6)$); 4.36 (dd, $J = 4.8, 10.4, H_{eq}-C(1)$); 4.16–4.04 ($m, H-C(2)$); 4.06 (br. t, $J \approx 9.6, H-C(4)$); 3.78–3.58 ($m, H-C(3), H-C(5)$); 3.67 (br. t, $J \approx 10.0, H_{ax}-C(1)$); 2.68 ($d, J = 2.1, C\equiv CH$). $^{13}C-NMR$ (50 MHz, $CDCl_3$): 138.87, 138.01, 137.57 (3s); 126.24–129.13 (several d); 101.41 ($d, PhCH$); 82.05 ($d, C(3)$); 79.58 (d); 78.56 ($s, C\equiv CH$); 78.18 (d); 77.61 ($s, C\equiv CH$); 75.48, 73.70 (2t, 2 $ArCH_2$); 69.04 ($t, C(1)$); 67.77 ($d, C(2)$); 66.15

(*d*, C(6)). CI-MS: 457 (21, $[M + 1]^+$), 365 (13, $[M - \text{Bn}]^+$), 91 (100). Anal. calc. for $\text{C}_{29}\text{H}_{28}\text{O}_5$ (456.54): C 76.30, H 6.18; found: C 76.18, H 6.18.

2,6-Anhydro-4,5-bis-O-(4-chlorobenzyl)-1,3-O-benzylidene-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (8). Under Ar, a soln. of **6** (11.2 g, 32.09 mmol) in DMF (120 ml) was cooled to 0°, treated with NaH (4.33 g, 90.35 mmol), stirred for 15 min, treated with 4-ClC₆H₄CH₂Cl (17.32 g, 107.5 mmol) and Bu₄Ni (39.7 g, 107.5 mmol), stirred at 0° for 3 h and at 23° for 2 h, treated dropwise with MeOH (30 ml), and diluted with H₂O (100 ml) and Et₂O (100 ml). The phases were separated, and the aq. phase was extracted with Et₂O (2 × 150 ml). The combined org. layers were washed with brine (100 ml), dried (MgSO₄), and evaporated. FC (cyclohexane/AcOEt 40:1 → 10:1) gave **8** (14.39 g, 86%). White foam. *R*_f (toluene) 0.29. $[\alpha]_{\text{D}}^{25} = +22.7$ (*c* = 1.0, CHCl₃). IR (CHCl₃): 3303*m*, 2870*w*, 2103*w*, 1599*m*, 1492*m*, 1459*w*, 1368*m*, 1089*s*, 999*m*. ¹H-NMR (300 MHz, CDCl₃): 7.52–7.26 (*m*, 13 arom. H); 5.57 (*s*, PhCH); 4.90, 4.79 (*dd*, *J* = 11.4, ArCH); 4.76 (*dd*, *J* = 2.4, 6.0, H–C(6)); 4.71, 4.70 (*dd*, *J* = 12.0, ArCH); 4.35 (*dd*, *J* = 4.5, 10.2, H_{eq}–C(1)); 4.08 (*dt*, *J* = 4.9, 9.9, H–C(2)); 4.00 (*t*, *J* = 9.1, H–C(4)); 3.71 (*t*, *J* = 10.1, H_{ax}–C(1)); 3.63 (*dd*, *J* = 6.0, 9.0, H–C(5)); 3.58 (*t*, *J* = 9.3, H–C(3)); 2.66 (*d*, *J* = 2.1, C≡CH). ¹³C-NMR (50 MHz, CDCl₃): 137.56, 137.43 (2*s* of ClC₆H₄); 136.54 (*s* of Ph); 134.10, 133.66 (2*s* of ClC₆H₄); 129.52 (2*d*); 129.49 (2*d*); 129.34 (*d*); 128.99 (2*d*); 128.74 (2*d*); 128.58 (2*d*); 126.33 (2*d*); 101.60 (*d*, PhCH); 82.02 (*d*, C(3)); 79.53, 78.40 (2*d*, C(4), C(5)); 78.43 (*s*, C≡CH); 77.94 (*s*, C≡CH); 74.55, 72.78 (2*t*, 2 ArCH₂); 69.03 (*t*, C(1)); 67.62 (*d*, C(2)); 66.22 (*d*, C(6)). HR-MALDI-MS: 547.103 (C₂₉H₂₅Cl₂NaO₅, $[M + \text{Na}]^+$; calc. 547.105). Anal. calc. for C₂₉H₂₆O₅Cl₂ (525.43): C 66.29, H 4.99, Cl 13.49; found: C 66.22, H 5.18, Cl 13.51

2,6-Anhydro-1,4,5-tri-O-benzyl-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (9). Under Ar, a suspension of **7** (13.3 g, 27.0 mmol) and 3-Å molecular sieves (6.70 g) in THF (500 ml) was treated with NaBH₃CN (6.80 g, 108 mmol), stirred at 23° for 15 min, treated with 1*M* HCl in Et₂O (120 ml, 119 mmol) over a period of 60 min, and stirred at 23° for 2 h. The suspension was filtered over *Celite* (washed with THF). Evaporation and FC (hexane/AcOEt 10:1 → 5:1) gave **9** (11.2 g, 84%). Transparent syrup. *R*_f (hexane/AcOEt 3:1) 0.40. $[\alpha]_{\text{D}}^{25} = +44.1$ (*c* = 1.10, CHCl₃). IR (CHCl₃): 3587*m*, 3305*m*, 3067*w*, 3008*m*, 2914*m*, 2672*m*, 2117*w*, 1603*w*, 1496*m*, 1454*m*, 1365*m*, 1262*m*, 1072*s*, 1028*s*, 911*w*. ¹H-NMR (200 MHz, CDCl₃): 7.40–7.26 (*m*, 15 arom. H); 5.03 (*d*, *J* = 11.6, PhCH); 4.81–4.73 (*m*, 3 PhCH); 4.78 (*dd*, *J* = 2.1, 5.8, H–C(6)); 4.63 (*br. d*, *J* ≈ 12.2, PhCH); 4.55 (*br. d*, *J* ≈ 12.2, PhCH); 4.04–3.95 (*td*, *J* ≈ 4.0, 10.0, H–C(2)); 3.87–3.57 (*m*, 2 H–C(1), H–C(3), H–C(4), H–C(5)); 2.64 (*d*, *J* ≈ 2.3, C≡CH); 2.50 (*d*, *J* = 2.1, HO–C(3)). ¹³C-NMR (50 MHz, CDCl₃): 138.75, 137.92, 137.77 (3*s*); 128.62–127.80 (several *d*); 82.37, 78.34 (2*d*, C(4), C(5)); 78.43 (*s*, C≡CH); 77.73 (*s*, C≡CH); 75.42, 73.64 (2*t*, 2 ArCH₂); 73.32 (*d*, C(2)); 72.94 (*t*, ArCH₂); 70.65 (*d*, C(3)); 69.54 (*t*, C(1)); 66.62 (*d*, C(6)). CI-MS: 476 (100, $[M + \text{NH}_4]^+$), 459 (4, $[M + \text{H}]^+$), 458 (3, M^+), 367 ($[M - \text{Bn}]^+$). Anal. calc. for C₂₉H₃₀O₅ (458.55): C 75.96, H 6.59; found: C 75.83, H 6.42.

2,6-Anhydro-4,5-bis-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (10). Under Ar, a soln. of **8** (160 mg, 0.30 mmol) in a soln. of 1% I₂ in MeOH (15 ml) was stirred under reflux for 15 min. After evaporation, the soln. of the residue in AcOEt (20 ml) was washed with sat. aq. Na₂S₂O₃ soln. (20 ml), H₂O (20 ml), and brine (30 ml), dried (MgSO₄), and evaporated. FC (toluene/AcOEt 2:1) gave **10** (74 mg, 71%). White foam. *R*_f (toluene/AcOEt 2:1) 0.13. $[\alpha]_{\text{D}}^{25} = +79.5$ (*c* = 0.95, CHCl₃). IR (CHCl₃): 3603*m*, 3432*m*, 3304*m*, 2102*w*, 1600*m*, 1493*m*, 1456*m*, 1364*m*, 1089*s*, 1039*s*. ¹H-NMR (200 MHz, CDCl₃): 7.35–7.23 (*m*, 8 arom. H); 4.92 (*d*, *J* = 11.6, ArCH); 4.77 (*t*, *J* = 2.0, 5.8, H–C(6)); 4.75 (*d*, *J* = 11.6), 4.65 (*d*, *J* = 11.8), 4.60 (*d*, *J* ≈ 12.0) (3 ArCH); 3.89–3.80 (*m*, 2 H–C(1), H–C(2)); 3.78 (*t*, *J* = 9.2, H–C(4)); 3.58 (*dt*, *J* = 3.4, 9.2, H–C(3)); 3.55 (*dd*, *J* = 5.8, 9.2, H–C(5)); 2.91 (*d*, *J* = 3.4, HO–C(3)); 2.66 (*d*, *J* = 2.0, C≡CH); 2.31 (*br. t*, *J* ≈ 5.2, HO–C(1)). ¹³C-NMR (50 MHz, CDCl₃): 137.27, 136.33, 134.16, 133.86 (4*s*); 129.48 (2*d*); 129.31 (2*d*); 128.97 (2*d*); 128.92 (2*d*); 82.39, 78.75 (2*d*, C(4), C(5)); 78.22 (*s*, C≡CH); 78.12 (*s*, C≡CH); 74.66 (*t*, ArCH₂); 74.44 (*d*, C(2)); 72.13 (*t*, ArCH₂); 70.13 (*d*, C(3)); 66.46 (*d*, C(6)); 62.33 (*t*, C(1)). FAB-MS: 435 (100, $[M - 1]^+$), 338 (65), 311 (24, $[M - 4\text{-ClC}_6\text{H}_4\text{CH}_2]^+$), 125 (98, 4-ClC₆H₄CH₂).

2,6-Anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (11). A mixture of **10** (640 mg, 1.46 mmol) and (Bu₃Sn)₂O (440 μl, 1.09 mmol) in toluene (9 ml) was stirred under reflux with azeotropic removal of H₂O (*Dean-Stark* apparatus) for 4 h. After evaporation, the residual soln. was treated with 4-ClC₆H₄CH₂Cl (470 mg, 2.92 mmol) and Bu₄Ni (647 mg, 1.75 mmol), and stirred for 16 h at 90°. After evaporation *in vacuo*, the soln. of the residue in AcOEt (25 ml) was treated with aq. KF (10 ml) and stirred for 1 h. The org. layer was separated, dried (MgSO₄), and evaporated. FC (toluene/AcOEt 1:0 → 2:1) gave **11** (614 mg, 75%). White foam. *R*_f (toluene/AcOEt 2:1) 0.49. $[\alpha]_{\text{D}}^{25} = +49.6$ (*c* = 0.95, CHCl₃). IR (CHCl₃): 3603*m*, 3499*m*, 3304*m*, 2102*w*, 1600*m*, 1492*s*, 1455*w*, 1408*m*, 1363*m*, 1089*s*, 1074*s*, 1016*s*. ¹H-NMR (300 MHz, CDCl₃): 7.33–7.24 (*m*, 12 arom. H); 4.90 (*d*, *J* = 12.0, ArCH); 4.77 (*dd*, *J* = 2.4, 5.4, H–C(6)); 4.73 (*d*, *J* = 11.7), 4.65 (*d*, *J* = 11.7); 4.60 (*d*, *J* = 11.4), 4.56 (*d*, *J* = 11.7), 4.50 (*d*, *J* = 12.0) (5 ArCH); 3.96 (*td*, *J* ≈ 3.9, 9.6, H–C(2)); 3.76 (*t*, *J* = 9.0, H–C(4)); 3.72 (*dd*, *J* = 4.2, 10.5, H–C(1)); 3.66 (*dd*, *J* = 3.5, 10.5, H–C(1)); 3.60 (*dt*, *J* = 2.4, 9.3,

H–C(3)); 3.56 (*dd*, $J = 5.7, 9.3$, H–C(5)); 2.63 (*d*, $J = 2.1$, C≡CH); 2.48 (*d*, $J = 3.0$, HO–C(3)). ¹³C-NMR (50 MHz, CDCl₃): 137.35, 136.59, 136.38, 134.15, 133.84, 133.76 (6s); 129.49 (2*d*); 129.33 (2*d*); 129.27 (2*d*); 128.97 (2*d*); 128.93 (2*d*); 128.83 (2*d*); 82.43, 78.56 (2*d*, C(4), C(5)); 78.27 (*s*, C≡CH); 78.03 (*s*, C≡CH); 74.64 (*t*, 2 ArCH₂); 73.35 (*d*, C(2)); 73.01, 72.14 (2*t*, 2 ArCH₂); 70.87 (*d*, C(2)); 69.82 (*t*, C(1)); 66.54 (*d*, C(6)). FAB-MS: 561 (32, [M + 1]⁺), 435 (13, [M – 4-C₆H₄CH₂]⁺), 125 (98, 4-C₆H₄CH₂⁺). Anal. calc. for C₂₉H₂₇Cl₃O₅ (561.89): C 61.99, H 4.84, Cl 18.93; found: C 62.19, H 4.83, Cl 19.11.

Phenyl-6-O-Acetyl-2,3-di-O-benzyl-4-deoxy-4-C-ethynyl-1-thio-α-D-glucopyranoside (13). A soln. of freshly prepared **12** [24] (17.70 g, 4.13 mmol) in AcOEt (500 ml) was treated with a soln. of PhSH (5.08 ml, 4.95 mmol) and Bu₄NSH (21.0 g, 62.0 mmol) in 1M Na₂CO₃ (500 ml) and stirred vigorously at 23° for 4 h. The mixture was diluted with AcOEt (500 ml) and aq. NaHCO₃ soln. (500 ml). The org. phase was washed with sat. NaHCO₃ soln. (2 × 400 ml), brine (400 ml), and dried (MgSO₄). Evaporation and FC (hexane/AcOEt 4:1 → 0:1) gave **13** (10.4 g, 50%). White solid. *R_f* (hexane/AcOEt 3:2) 0.41. M.p. 78–80°. [α]_D²⁵ = +161.0 ($c = 1.00$, CH₂Cl₂). IR (CH₂Cl₂): 3302s, 3033m, 1953w (br.), 1741s, 1605m, 1584m, 1496m, 1481m, 1454m, 1440m, 1386m, 1368s, 1237s, 1102s (br.), 1038s, 911w, 653m. ¹H-NMR (500 MHz, CDCl₃, assignment based on a DQF-COSY spectrum): 7.24–7.49 (*m*, 15 arom. H); 5.64 (*d*, $J = 5.3$, H–C(1)); 4.93 (*d*, $J = 10.5$, ArCH); 4.91 (*d*, $J = 10.5$, ArCH); 4.76 (*d*, $J = 11.8$, ArCH); 4.70 (*d*, $J = 11.8$, ArCH); 4.52 (*ddd*, $J = 3.2, 4.7, 10.8$, H–C(5)); 4.34–4.32 (*m*, 2 H–C(6)); 3.87 (*t*, $J \approx 9.6$, H–C(3)); 3.78 (*dd*, $J = 5.4, 9.4$, H–C(2)); 2.68 (*dt*, $J = 2.3, 10.6$, H–C(4)); 2.21 (*d*, $J = 2.3$, C≡CH); 1.99 (*s*, AcO). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HSQC spectrum): 170.62 (*s*, C=O); 138.27, 137.60, 133.84 (3*s*); 131.70–127.34 (several *d*); 87.03 (*d*, C(1)); 80.47 (*s*, C≡CH); 79.41 (*d*, C(2)); 79.29 (*d*, C(3)); 76.11, 72.54 (2*t*, 2 ArCH₂); 72.44 (*s*, C≡CH); 69.57 (*d*, C(5)); 64.16 (*t*, C(6)); 37.00 (*d*, C(4)); 20.74 (*q*, Me). FAB-MS: 503 ([M + 1]⁺). Anal. calc. for C₃₀H₃₀O₅S (502.63): C 71.69, H 6.02; found: C 71.74, H 6.11.

Phenyl 2,3,6-Tris-O-(4-chlorobenzyl)-4-deoxy-4-C-ethynyl-1-thio-β-D-glucopyranoside (15). Under Ar, a soln. of **14** [25] (2.5 g, 8.9 mmol) in DMF (40 ml) was cooled to 0°, treated with NaH (1.41 g, 29.4 mmol), stirred for 15 min, treated with 4-ClC₆H₄CH₂Cl (5.0 g, 31.2 mmol) and Bu₄NI (9.88 g, 26.75 mmol), stirred at 0° for 3 h and at 23° for 3 h, treated dropwise with MeOH (5 ml), and diluted with H₂O (50 ml) and Et₂O (50 ml). The phases were separated, and the aq. phase was extracted with Et₂O (2 × 50 ml). The combined org. layers were washed with brine (50 ml), dried (MgSO₄), and evaporated. FC (cyclohexane/AcOEt 7:1) gave **15** (5.55 g, 90%). White foam. *R_f* (hexane/AcOEt 10:4) 0.46. [α]_D²⁵ = +21.0 ($c = 1.00$, CHCl₃). IR (CHCl₃): 3305m, 2908m, 2868m, 1599m, 1491m, 1407w, 1276w, 1087s, 1017s. ¹H-NMR (300 MHz, CDCl₃): 7.56–7.53 (*m*, 2 arom. H); 7.36–7.24 (*m*, 15 arom. H); 4.99 (*d*, $J = 10.8$), 4.87 (*d*, $J = 10.8$), 4.79 (*d*, $J = 11.2$) (3 ArCH); 4.72 (*d*, $J = 9.4$, H–C(1)); 4.67 (*d*, $J = 10.8$), 4.58 (*d*, $J = 12.2$), 4.57 (*d*, $J = 12.4$) (3 ArCH); 3.94 (*dd*, $J = 1.6, 10.8$, H–C(6)); 3.76 (*dd*, $J = 5.4, 10.8$, H–C(6)); 3.66 (*ddd*, $J = 1.6, 5.4, 10.8$, H–C(5)); 3.60 (*dd*, $J = 8.8, 10.8$, H–C(3)); 3.37 (*dd*, $J = 8.8, 9.6$, H–C(2)); 2.80 (*dt*, $J = 2.4, 10.4$, H–C(4)); 2.19 (*d*, $J = 2.0$, C≡CH). ¹³C-NMR (75 MHz, CDCl₃): 137.04, 136.85, 136.77 (3*s*); 133.90 (3*s*); 133.55 (*s*); 132.04 (2*d*); 129.59 (2*d*); 129.56 (2*d*); 129.25 (2*d*); 129.17 (2*d*); 128.85 (2*d*); 128.81 (2*d*); 128.73 (2*d*); 127.87 (*d*); 87.91 (*d*, C(1)); 84.43 (*d*, C(2)); 81.08 (*s*, C≡CH); 80.65 (*d*, C(3)); 79.01 (*d*, C(5)); 75.13, 74.83, 72.72 (3*t*, 3 ArCH₂); 72.72 (*s*, C≡CH); 70.45 (*t*, C(6)); 37.18 (*d*, C(4)). HR-MALDI-MS: 629.09 (C₃₁H₃₁Cl₃NaO₄S, [M + Na]⁺; calc. 628.99). Anal. calc. for C₃₁H₃₁Cl₃O₄S (605.7): C 64.27, H 4.78; found: C 64.15, H 5.01.

Icosa-O-acetylmaltohexaose (18) [33]. Under N₂ and with vigorous stirring, **17** [33] (67.0 g, 0.038 mol) was dissolved in Ac₂O (2000 ml) at 23°. The soln. was cooled to 0° and treated with 70% HClO₄ (27.0 ml, 0.174 mol), stirred for 20 h, and warmed to 23°. After 2 h at 23°, when TLC showed complete disappearance of **17**, the soln. was cooled to 0° and neutralized by the addition of a 10% aq. NaHCO₃ soln. (1600 ml). The mixture was concentrated to 1/4 of its original volume (*ca.* 1000 ml) under reduced pressure. The remaining soln. was diluted with AcOEt (1000 ml) and washed with H₂O (1000 ml). The aq. phase was extracted with AcOEt (3 × 500 ml). The combined org. layers were dried (MgSO₄) and evaporated. Recrystallisation from EtOH gave α -**18**/ β -**18** > 9:1 (66.2 g, 95%). Off-white solid. *R_f* (hexane/AcOEt 1:3) 0.30. *R_f* (CH₂Cl₂/EtOH 35:1) 0.41. M.p. 79–80°. ¹H- and ¹³C-NMR data are in agreement with the values in [12]. MALDI-MS: 1871 ([M + K]⁺), 1854 ([M + Na]⁺).

Phenyl 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl-[(1 → 4)-2,3,6-tri-O-acetyl-α-D-glucopyranosyl]_r-(1 → 4)-2,3,6-tri-O-acetyl-1-thio-β-D-glucopyranoside (19) [23]. Under N₂, a soln. of α -**18**/ β -**18** > 9:1 (58.0 g, 31.6 mmol) in dry CH₂Cl₂ (300 ml) was treated with ZnI₂ (46.2 g, 0.148 mol) and *S*-(trimethylsilyl)thiophenol (27.4 ml, 0.148 mol) and stirred at 23° for 48 h. The mixture was filtered over *Celite*. The filtrate was washed with 1M HCl (100 ml), sat. aq. NaHCO₃ soln. (2 × 80 ml), H₂O (2 × 80 ml), and brine (80 ml), dried (MgSO₄) and evaporated. FC (hexane/AcOEt 2:3 → 0:1) gave **19** (50.5 g, 85%). White foam. *R_f* (hexane/AcOEt 1:3) 0.44. ¹H- and ¹³C-NMR data are in agreement with the values in [23]. MALDI-MS: 1922 ([M + K]⁺), 1905 ([M + Na]⁺).

*Phenyl α -D-Glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl] $_4$ -(1 \rightarrow 4)-I-thio- β -D-glucopyranoside (**20**)* [23]. A soln. of **19** (20.6 g, 10.9 mmol) in MeOH/H₂O 1 : 1 (800 ml) was treated with 1M NaOMe in MeOH (40 ml), stirred for 20 h at 23°, treated with Amberlite IR-120 (H⁺ form) and filtered. Evaporation and FC (CH₂Cl₂/MeOH/H₂O 75 : 50 : 12) gave **20** (11.2 g, 94%). *R*_f (CH₂Cl₂/MeOH/H₂O 75 : 50 : 12) 0.34. M.p. 180° (dec.). MALDI-MS: 1121 ([M + K]⁺), 1106 ([M + Na]⁺). ¹H- and ¹³C-NMR data are in agreement with the values in [23].

*Phenyl 4,6-O-Benzylidene- α -D-glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl] $_4$ -(1 \rightarrow 4)-I-thio- β -D-glucopyranoside (**21**)*. A soln. of **20** (4.65 g, 4.29 mmol) in pyridine (150 ml) was treated with α,α -dibromotoluene (5.55 ml, 33.5 mmol), warmed from 25 to 95° over a period of 7 h, and stirred at 95° for 72 h. The mixture was filtered, and the residue was washed with pyridine (50 ml). The combined filtrate and washings were evaporated. FC (CH₂Cl₂/MeOH/H₂O 75 : 50 : 12; residue adsorbed on silica gel pre-treated with Et₃N) gave crude **21** and **20**. Compound **21** was used immediately as isolated. *R*_f (CH₂Cl₂/MeOH/H₂O 75 : 50 : 12) 0.75. ¹H-NMR (300 MHz, CD₃OD): 7.60–7.42 (*m*, 4 arom. H); 7.40–7.21 (*m*, 6 arom. H); 5.57 (*s*, PhCH); 5.21–5.15 (*m*, H–C(1^{H-VI})); 4.60 (*d*, *J* = 10.0, H–C(1^H)); 4.22 (*dd*, *J* = 4.4, 9.6, H_{eq}–C(6^{VI})); 3.98–3.38 (*m*, 35 H). ¹³C-NMR (75 MHz, CD₃OD): 139.42, 135.36 (2*s*); 133.20 (2*d*); 130.28 (2*d*); 130.22 (2*d*); 129.39 (2*d*); 128.75 (2*d*); 127.84 (2*d*); 103.70, 103.30, 102.86 (3 C) (3*d*, C(1^{H-VI})); 102.75 (PhCH); 89.55 (*d*, C(1^H)); 82.74, 81.83, 81.43 (2 C), 80.81 (2 C) (4*d*, C(4^{H-VI})); 79.62 (*d*, C(5^H)); 75.13 (4 C), 75.05 (2 C), 74.03 (3 C), 73.63 (2 C), 73.52 (4 C), 72.32 (6*d*, C(2^{H-VI}), C(3^{H-VI}), C(5^{H-VI})); 70.00 (*t*, C(6^{VI})); 65.22 (C(5^{VI})); 62.53 (2 C), 62.38 (3 C) (2*t*, C(6^{H-VI})). MALDI-MS: 1194 ([M + Na]⁺).

*Phenyl 2,3-Di-O-benzyl-4,6-O-benzylidene- α -D-glucopyranosyl-[(1 \rightarrow 4)-2,3,6-tri-O-benzyl- α -D-glucopyranosyl] $_4$ -(1 \rightarrow 4)-2,3,6-tri-O-benzyl-1-thio- β -D-glucopyranoside (**22**)* [23]. A soln. of **21** (5.03 g, 4.29 mmol) in DMF (80 ml) was cooled to 0°, treated with NaH (11.96 g), BnBr (25.51 ml, 214.55 mmol), Et₄Ni (141 mg, 0.055 mmol), and imidazole (37.3 mg, 0.055 mmol), warmed to 23°, and stirred for 20 h. The mixture was cooled to 0° and treated dropwise with MeOH (50 ml) and H₂O (50 ml). The mixture was diluted with CH₂Cl₂ (200 ml). The org. layer was washed with sat. aq. NaHCO₃ soln. (2 \times 80 ml), H₂O (2 \times 80 ml), and brine (80 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 40 : 1 \rightarrow 20 : 1) gave **22** (9.06 g, 78% from **20**). White solid. *R*_f (toluene/AcOEt 18 : 1) 0.55. ¹H- and ¹³C-NMR data are in agreement with the values in [23]. MALDI-MS: 2744 ([M + K]⁺), 2726 ([M + Na]⁺).

*Phenyl 2,3-Bis-O-(4-chlorobenzyl)-4,6-O-benzylidene- α -D-glucopyranosyl-[(1 \rightarrow 4)-2,3,6-tri-O-(4-chlorobenzyl)- α -D-glucopyranosyl] $_4$ -(1 \rightarrow 4)-2,3,6-tri-O-(4-chlorobenzyl)-1-thio- β -D-glucopyranoside (**23**)*. A soln. of **21** (5.70 g, 4.86 mmol) in DMF (180 ml) was cooled to 0°, treated with NaH (17 g, 354 mmol), stirred for 30 min, treated with 4-ClC₆H₄CH₂Cl (56 g, 350 mmol) and Bu₄Ni (44 g, 121 mmol), stirred at 0° for 1 h and at 23° for 12 h. The soln. was cooled to 0°, treated dropwise with MeOH (20 ml), and diluted with H₂O (200 ml) and Et₂O (200 ml). The phases were separated, and the aq. phases were extracted with Et₂O (2 \times 200 ml). The combined org. layers were washed with brine (200 ml), dried (MgSO₄), and evaporated. FC (toluene/AcOEt 60 : 1 \rightarrow 30 : 1) gave **23** (13.5 g, 80% from **20**). White foam. *R*_f (toluene/AcOEt 40 : 1) 0.29. [α]_D²⁵ = +55.1 (*c* = 0.95, CHCl₃). IR (CHCl₃): 2927*m*, 2867*m*, 1600*w*, 1492*m*, 1362*m*, 1155*m*, 1090*s*, 1016*s*. ¹H-NMR (500 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 7.55–7.52 (*m*, 2 arom. H); 7.48–7.43 (*m*, 2 arom. H); 7.41–7.36 (*m*, 2 arom. H); 7.30–6.81 (*m*, 72 arom. H); 5.53 (*s*, PhCH); 5.52 (*d*, *J* = 4.4), 5.51 (*d*, *J* = 4.1), 5.47 (*d*, *J* = 3.6), 5.43 (*d*, *J* = 3.6), 5.40 (*d*, *J* = 3.6) (H–C(1^{H-VI})); 4.840 (*d*, *J* = 11.8), 4.838 (*d*, *J* \approx 11.5), 4.80 (*d*, *J* = 12.0), 4.76 (*d*, *J* = 12.0), 4.72 (*d*, *J* \approx 12.0), 4.70 (*d*, *J* = 11.9) (6 ArCH); 4.68 (*d*, *J* \approx 9.7, H–C(1^H)); 4.66 (*d*, *J* = 11.7), 4.64 (*d*, *J* = 11.0), 4.62 (*d*, *J* = 11.4), 4.59 (*d*, *J* \approx 12.0), 4.58 (*d*, *J* = 11.7), 4.56 (*d*, *J* = 12.0), 4.53 (*d*, *J* = 12.1), 4.52 (*d*, *J* = 12.0), 4.49 (*d*, *J* = 11.0), 4.48 (*d*, *J* = 12.0), 4.44 (*d*, *J* = 11.3), 4.42 (*d*, *J* = 12.1), 4.39 (*d*, *J* = 11.2) (13 ArCH); 4.36–4.27 (*m*, 15 ArCH); 4.05 (*dd*, *J* = 4.6, 10.1, H_{eq}–C(6^{VI})); 4.02 (*t*, *J* = 9.6), 3.99 (*t*, *J* = 9.4), 3.97 (*t*, *J* = 9.5, 2 H) (4 H–C(4)); 3.93–3.86 (*m*, irradi. at 3.43 \rightarrow change, H–C(3^{H-VI}), 1 H–C(4), 1 H–C(5), H–C(6^H)); 3.83–3.73 (*m*, 4 H–C(5), H⁺–C(6^H)); 3.72 (*t*, *J* = 8.8, H–C(3^H)); 3.70–3.67 (*m*, 4 H–C(6)); 3.61 (*t*, *J* = 10.2, H_{ax}–C(6^{VI})); 3.59 (*t*, *J* = 9.4, H–C(4^{VI})); 3.55 (*ddd*, *J* = 1.3, 3.8, 9.6, H–C(5^H)); 3.52 (*dd*, *J* = 8.8, 9.6, irradi. at 4.68 \rightarrow change, H–C(2^H)); 3.50–3.39 (*m*, irradi. at 5.48 \rightarrow change, H–C(2^{H-VI}), 4 H⁺–C(6)). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 137.87–135.87 (several *s*); 133.77–133.04 (several *s*); 131.99–125.30 (several *d*); 101.25 (*d*, PhCH); 97.83 (*d*, C(1^{VI})); 96.95, 96.67 (2 C), 96.46 (3*d*, C(1^{H-VI})); 87.37 (*d*, C(1^H)); 86.35 (*d*, C(3^H)); 82.30 (*d*, C(4^{VI})); 81.60, 81.36, 81.33, 81.20 (4*d*, C(3^{H-VI})); 80.82 (*d*, C(2^H)); 79.56 (2 C), 79.52, 79.38 (3*d*, C(2^{H-VI})); 78.98 (*d*, C(5^H)); 78.76 (*d*, C(2^{VI})); 78.61 (*d*, C(3^{VI})); 74.45–72.30 (several *t*, 17 ArCH₂); 74.55, 74.18, 74.09, 73.52, 73.25 (5*d*, C(4^{H-VI})); 70.92 (3 C), 70.72 (2*d*, C(5^{H-VI})); 69.09 (*t*, C(6^H)); 68.98, 68.77, 68.72, 68.17 (4*t*, C(6^{H-VI})); 68.85 (*t*, C(6^{VI})); 63.38 (*d*, C(5^{VI})). MALDI-MS: 3309.5 ([M + Na]⁺). Anal. calc. for C₁₆₈H₁₅₅Cl₁₇O₃₀S (3288.82): C 61.35, H 4.74, Cl 18.33; found: C 61.58, H 4.80, Cl 18.06.

Glycosylation of 9 with 22. Under Ar. a suspension of **9** (1.02 g, 2.22 mmol), **22** (5.00 g, 1.85 mmol), and 3-Å molecular sieves (2.50 g) in dry Et₂O (100 ml) was stirred at –60° for 1 h, treated with NIS (0.750 g, 3.33 mmol) and TfOH (82.0 µl, 0.925 mmol), and stirred for 48 h. The suspension was filtered over *Celite*, washed with 10% aq. Na₂S₂O₃ soln. (40 ml), sat. aq. NaHCO₃ soln. (2 × 30 ml), H₂O (2 × 30 ml), and brine (30 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 40:1 → 20:1) gave **24** (3.64 g, 64%) and **25** (1.21 g, 22%).

2,3-Di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-[(1 → 4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)]₅-(1 → 3)-2,6-anhydro-1,4,5-tri-O-benzyl-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (24). White foam. *R*_f (toluene/AcOEt 18:1) 0.48. M.p. 60–61°. [*α*]_D²⁵ = +91.3 (*c* = 1.02, CH₂Cl₂). IR (CH₂Cl₂): 3300w, 3032m, 2868m, 1605w, 1496m, 1420m, 1364m, 1208m, 1154m, 1093s, 1028s, 913m. ¹H-NMR (500 MHz, CDCl₃, assignment based on COSY spectra): 7.49 (*dd*, *J* = 2.2, 7.9, 2 arom. H); 7.40–7.00 (*m*, 103 arom. H); 5.68 (*d*, *J* = 3.8), 5.66 (*d*, *J* = 3.6), 5.64 (*d*, *J* = 3.6), 5.62 (*d*, *J* = 3.6), 5.60 (*d*, *J* = 3.6), 5.54 (*d*, *J* = 3.5) (H–C(1^{II-VII})); 5.52 (*s*, PhCH); 5.02–4.75 (*m*, 9 ArCH); 4.74 (*dd*, *J* = 2.3, 5.8, H–C(6^I)); 4.73–4.72 (*m*, 31 ArCH); 4.13–3.97 (*m*, H–C(3^I), H–C(3^{II-VII}), H–C(4^I), H–C(4^{II-VI}), H_{ax}–C(6^{VII})); 3.94–3.81 (*m*, H–C(2^I), H_{eq}–C(6^{VII})); 3.78–3.64 (*m*, H–C(5^I), 6 H–C(6)); 3.60–3.46 (*m*, H–C(2^{II-VII}), H–C(4^{VII}), 6 H[′]–C(6)); 2.64 (*d*, *J* = 2.3, C≡CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 139.01–137.65 (several *s*); 128.81–126.07 (several *d*); 101.14 (*d*, PhCH); 97.46, 96.70, 96.23 (2 C), 96.20 (*4d*, C(1^{II-VII})); 82.75 (*d*, C(4^I)); 82.35 (*d*, C(4^{VII})); 81.16, 81.85, 81.70, 81.67, 81.51 (*5d*, C(3^{II-VI})); 79.71, 79.57, 79.54, 79.44, 79.40 (*5d*, C(2^{II-VII})); 78.90 (*d*, C(2^{VII})); 78.74 (*d*, C(3^{VII})); 78.72 (*d*, C(5^I)); 78.63 (*s*, C≡CH); 77.81 (*s*, C≡CH); 75.34–72.39 (several *t*, 20 ArCH₂); 73.98, 73.86, 73.07, 72.70, 72.57, 72.10 (*6d*, C(3^I), C(4^{II-VI})); 70.85, 70.81 (2 C), 70.79, 70.75, 70.57 (*5d*, C(2^I), C(5^{II-VI})); 68.97, 68.69 (5 C), 68.12 (3*t*, C(1^I), C(6^{II-VII})); 66.38 (*d*, C(6^I)); 63.21 (*d*, C(5^{VII})). MALDI-MS: 3091 ([*M* + *K*]⁺), 3074 ([*M* + *Na*]⁺). Anal. calc. for C₁₉₁H₁₉₆O₃₅ (3051.66): C 75.18, H 6.47; found: C 74.94, H 6.51.

2,3-Di-O-benzyl-4,6-O-benzylidene-α-D-glucopyranosyl-[(1 → 4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)]₄-(1 → 4)-(2,3,6-tri-O-benzyl-β-D-glucopyranosyl)-(1 → 4)-2,6-anhydro-1,4,5-tri-O-benzyl-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (25). White foam. *R*_f (toluene/AcOEt 18:1) 0.39. M.p. 57–60°. [*α*]_D²⁵ = 78.9 (*c* = 1.00, CH₂Cl₂). IR (CH₂Cl₂): 3300w, 3032m, 2869m, 1605w, 1496m, 1453m, 1419m, 1364m, 1208m, 1154m, 1092s, 1028s. ¹H-NMR (500 MHz, CDCl₃, assignment based on COSY spectra): 7.50 (*dd*, *J* = 2.2, 7.8, 2 arom. H); 7.39–7.35 (*m*, 4 arom. H); 7.39–7.00 (*d*, 99 arom. H); 5.68 (*t*, *J* = 4.0, 2 H), 5.62 (*t*, *J* = 4.0, 2 H), 5.53 (*d*, *J* = 3.3) (H–C(1^{III-VII})); 5.53 (*s*, PhCH); 5.07 (*d*, *J* = 11.5, ArCH); 4.91–4.55 (*m*, 20 ArCH); 4.51–4.36 (*m*, 18 ArCH, H–C(6^I), H–C(1^{II})); 4.29 (*d*, *J* = 12.0, ArCH); 4.17–3.96 (*m*, H–C(3^I), H–C(3^{III-VII}), H–C(4^{II}), H–C(4^{III-VI}), H_{ax}–C(6^{VII})); 3.94–3.79 (*m*, H–C(1^I), H–C(2^I), H–C(4^I), H–C(5^{III-VII})); 3.79–3.68 (*m*, 5 H–C(6), H_{eq}–C(6^{VII})); 3.59–3.44 (*m*, H[′]–C(1^I), H–C(2^{II-VII}), H–C(3^{II}), H–C(4^{VII}), H–C(5^I), 5 H[′]–C(6)); 3.41 (*t*, *J* = 8.0, H–C(2^{II})); 3.30 (*br. ddd*, *J* = 1.5, 3.5, 9.6, H–C(5^{II})); 2.57 (*d*, *J* = 2.3, C≡CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 139.39–137.66 (several *s*); 128.82–126.08 (several *d*); 102.20 (*d*, C(1^{II})); 101.15 (*d*, PhCH); 97.46, 96.74, 96.42, 96.22, 96.12 (*5d*, C(1^{III-VII})); 84.74 (*d*, C(3^{II})); 82.56 (*d*, C(2^{II})); 82.36 (*d*, C(4^{VII})); 81.87, 81.67 (2 C), 81.58 (*3d*, C(3^{III-VI})); 81.16 (*d*, C(3^I)); 79.74, 79.57, 79.48, 79.33 (*4d*, C(2^{III-VI})); 78.90 (*d*, C(2^{VII})); 78.73 (*2d*, C(3^{VII}), C(5^I)); 78.68 (*s*, C≡CH); 77.85 (*s*, C≡CH); 76.04, 74.35 (*2d*, C(3^I), C(4^{II})); 75.02 (*d*, C(5^{II})); 73.81 (*d*, C(2^I)); 73.09, 72.85, 72.19, 72.09 (*4d*, C(4^{III-VI})); 75.30–72.56 (several *t*, 20 ArCH₂); 70.84 (3 C), 70.78, 70.58 (*3d*, C(5^{II-VI})); 69.10, 68.98, 68.69 (2 C), 68.61 (2 C) (4*t*, C(6^{II-VII})); 67.89 (*t*, C(1^I)); 66.81 (*d*, C(6^I)); 63.22 (*d*, C(5^{VII})). MALDI-MS: 3090 ([*M* + *K*]⁺), 3074 ([*M* + *Na*]⁺). Anal. calc. for C₁₉₁H₁₉₆O₃₅ · 2 H₂O (3087.70): C 74.30, H 6.53; found: C 74.34, H 6.83.

Glycosidation of 11 with 23. Under Ar, a suspension of **11** (95 mg, 0.17 mmol), **23** (500 mg, 0.15 mmol), and 3-Å molecular sieves (500 mg) in dry Et₂O (20 ml) was stirred at –60° for 1 h, treated with NIS (61 mg, 0.27 mmol) and TfOH (7 µl, 0.085 mmol) and stirred for 48 h. The suspension was filtered over *Celite*. The filtrate was washed with 10% aq. Na₂S₂O₃ soln. (10 ml), sat. aq. NaHCO₃ soln. (2 × 10 ml), H₂O (2 × 10 ml), and brine (10 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 40:1 → 20:1) gave **26** (316 mg, 55%) and **27** (229 mg, 40%).

2,3-Bis-O-(4-chlorobenzyl)-4,6-O-benzylidene-α-D-glucopyranosyl-[(1 → 4)-(2,3,6-tris-O-(4-chlorobenzyl)-α-D-glucopyranosyl)]₅-(1 → 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (26). White foam. *R*_f (toluene/AcOEt 18:1) 0.36. [*α*]_D²⁵ = +57.5 (*c* = 1.0, CHCl₃). IR (CHCl₃): 3304w, 2927m, 2867m, 1600w, 1492m, 1362m, 1155m, 1090s, 1016s. ¹H-NMR (500 MHz, CDCl₃, assignment based on a HSQC-GRASP spectrum): 7.45–7.34 (*m*, 5 arom. H); 7.27–6.84 (*m*, 80 arom. H); 5.53 (*s*, PhCH); 5.53 (*d*, *J* ≈ 3.5), 5.52 (*d*, *J* = 3.7), 5.51 (*d*, *J* = 3.8), 5.483 (*d*, *J* = 3.5), 5.473 (*d*, *J* = 3.5), 5.44 (*d*, *J* = 3.5) (H–C(1^{II-VII})); 4.89 (*d*, *J* = 11.9), 4.83 (*d*, *J* = 11.7) (2 ArCH); 4.79 (*dd*, *J* = 2.4, 5.7, H–C(6^I)); 4.77 (*d*, *J* = 12.1), 4.74 (*d*, *J* = 11.6), 4.71 (*d*, *J* = 12.1), 4.68 (*d*, *J* = 12.0) (4 ArCH); 4.67–4.56 (*m*, 10 ArCH); 4.55 (*d*, *J* = 11.9), 4.52 (*d*, *J* = 11.9),

4.465 (*d*, *J* = 11.9), 4.455 (*d*, *J* = 12.2), 4.435 (*d*, *J* = 12.1), 4.41 (*d*, *J* = 12.1) (6 ArCH); 4.40–4.29 (*m*, 18 ArCH); 4.06 (*dd*, *J* = 4.8, 10.3, H_{eq}–C(6^{VII})); 4.05–3.86 (*m*, H–C(1^I), H–C(2^I), H–C(3^I), H–C(4^I), H–C(3^{II-VII}), H–C(4^{II-VII})); 3.81–3.75 (*m*, H–C(5^{II-VII})); 3.69–3.64 (*m*, H–C(6^{II-VI})); 3.63–3.58 (*m*, H–C(5^I), H'–C(1^I), H_{ax}–C(6^{VII})); 3.58 (*t*, *J* = 9.4, H–C(4^{VII})); 3.48–3.40 (*m*, H–C(2^{II-VII}), H'–C(6^{II-VI})); 2.68 (*d*, *J* = 2.3, C≡CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 137.27–135.88 (several *s*); 133.95–133.00 (several *s*); 129.58–125.92 (several *d*); 101.26 (*d*, PhCH); 97.83 (*d*, C(1^{VII})); 96.66, 96.60, 96.45 (2 C), 96.42 (4*d*, C(1^{II-VI})); 82.47 (*d*, C(4^I)); 82.31 (*d*, C(4^{VII})); 81.61, 81.40, 81.37 (2 C), 81.22 (4*d*, C(3^{II-VI})); 79.63, 79.58 (2 C), 79.48, 79.37 (4*d*, C(2^{II-VI})); 78.86 (*d*, C(5^I)); 78.77 (*d*, C(2^{VII})); 78.62 (*d*, C(3^{VII})); 78.17 (*br. s*, C≡CH); 74.18–72.10 (several *t*, 20 ArCH₂); 74.07, 73.67, 73.62, 73.45, 73.16, 73.04 (6*d*, C(3^I), C(4^{II-VI})); 70.93 (2 C), 70.88 (2 C), 70.82, 70.72 (4*d*, C(2^I), C(5^{II-VI})); 68.98 (2 C); 68.85 (3 C), 68.76 (2 C) (3*t*, C(1^I), C(6^{II-VII})); 66.11 (*d*, C(6^I)); 63.38 (*d*, C(5^{VII})). MALDI-MS: 3763.1 ([*M* + Na]⁺). Anal. calc. for C₁₉₁H₁₇₆Cl₂₀O₃₅ (3740.52): C 61.33, H 4.74, Cl 18.96; found: C 61.52, H 4.95, Cl 19.24.

2,3-Bis-O-(4-chlorobenzyl)-4,6-O-benzylidene- α -D-glucopyranosyl]-[(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl]_{*r*}-(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**27**). White foam. *R*_f (toluene/AcOEt 18 : 1) 0.30. [α]_D²⁵ = +50.1 (*c* = 1.00, CHCl₃). IR (CHCl₃): 3303w, 2869m, 1600w, 1492m, 1465m, 1408m, 1361m, 1090s, 1036s. ¹H-NMR (500 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 7.47–7.40 (*m*, 5 arom. H); 7.31–6.87 (*m*, 80 arom. H); 5.55 (*s*, PhCH), 5.55 (*d*, *J* \approx 3.7), 5.53 (*d*, *J* = 3.7), 5.51 (*br. d*, *J* \approx 2.9, 2 H), 5.41 (*d*, *J* = 3.5) (H–C(1^{III-VII})); 4.98 (*d*, *J* = 12.0), 4.85 (*d*, *J* = 11.7), 4.81 (*d*, *J* = 12.0), 4.76 (*d*, *J* \approx 11.4) (4 ArCH); 4.76 (*dd*, *J* = 2.4, 5.8, H–C(6^I)); 4.75–4.59 (*m*, 15 ArCH); 4.57 (*d*, *J* = 12.1), 4.54 (*d*, *J* = 11.6), 4.48 (*d*, *J* \approx 12.0), 4.44 (*d*, *J* = 12.1) (4 ArCH); 4.41–4.29 (*m*, 18 ArCH); 4.04 (*d*, *J* = 7.7, H–C(1^{II})); 4.25 (*d*, *J* = 12.2, ArCH); 4.09 (*dd*, *J* = 4.6, 10.3, H_{eq}–C(6^{VII})); 4.40 (*t*, *J* = 9.5, H–C(4)); 4.02 (*t*, *J* = 9.4, 2 H–C(4)); 3.98–3.89 (*m*, H–C(3^I), H–C(3^{III-VII}), 2 H–C(4), 1 H–C(5)); 3.87–3.78 (*m*, H–C(1^I), H–C(2^I), 3 H–C(5), H–C(5^{VII})); 3.77 (*t*, *J* = 9.1, H–C(4^I)); 3.76–3.69 (*m*, H–C(6^{II-VI})); 3.64 (*t*, *J* = 10.3, H_{ax}–C(6^{VII})); 3.61 (*t*, *J* = 9.5, H–C(4^{VII})); 3.57 (*br. dd*, *J* \approx 1.5, 10.5, H'–C(1^I)); 3.54 (*dd*, *J* = 5.8, 9.3, H–C(5^I)); 3.535 (*br. dd*, *J* \approx 1.5, 11.0, H'–C(6^{II})); 3.49 (*t*, *J* = 8.9, H–C(3^{II})); 3.48–3.42 (*m*, H–C(2^{III-VII}), H–C(3^{II}), H'–C(6^{III-VII})); 3.34 (*dd*, *J* = 8.0, 9.0, H–C(2^{II})); 3.29 (*br. ddd*, *J* \approx 1.5, 3.5, 9.5, H–C(5^{II})); 2.64 (*d*, *J* = 2.3, C≡CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 137.87–135.89 (several *s*); 133.79–132.87 (several *s*); 129.51–125.30 (several *d*); 102.15 (*d*, C(1^{II})); 101.25 (*d*, PhCH); 97.82 (*d*, C(1^{VII})); 96.86, 96.62 (2 C), 96.44 (3*d*, C(1^{III-VI})); 84.67 (*d*, C(3^{II})); 82.33 (*d*, C(2^{II}), C(4^{VII})); 81.61, 81.37, 81.34, 81.24 (4*d*, C(3^{II-VI})); 81.01 (*d*, C(4^I)); 79.56 (3 C), 79.38 (2*d*, C(2^{III-VI})); 78.77 (*d*, C(2^{VII})); 78.62 (*d*, C(3^{VII})); 78.15 (*d*, C(5^I)); 78.15 (*s*, C≡CH); 77.76 (*s*, C≡CH); 75.91, 75.06 (2*d*, C(3^I), C(4^{II})); 74.97 (*d*, C(5^{II})); *ca.* 74.1 (*d*, C(2^I)); 74.0–73.0 (4*d*, C(4^{III-VI})); 74.97–72.33 (several *t*, 20 ArCH₂); 70.94 (3 C), 70.71 (2*d*, C(5^{III-VI})); 69.05 (*t*, C(6^{II})); 68.85, 68.77 (2 C), 68.72 (2 C) (3*t*, C(6^{III-VII})); 67.90 (*t*, C(1^I)); 66.43 (*d*, C(6^I)); 63.38 (*d*, C(5^{VII})). MALDI-MS: 3763.6 ([*M* + Na]⁺). Anal. calc. for C₁₉₁H₁₇₆Cl₂₀O₃₅ (3740.52): C 61.33, H 4.74; found: C 61.37, H 4.87.

[(1 \rightarrow 4)-2,3,6-Tri-O-benzyl- α -D-glucopyranosyl]_{*o*}-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tri-O-benzyl-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**28**). A suspension of **24** (2.52 g, 0.826 mol), dried 3-Å molecular sieves (1.50 g), Me₃N·BH₃ (1.20 g, 16.5 mmol), and AlCl₃ (2.20 g, 16.5 mmol) in THF (100 ml) was stirred at 23° for 48 h. The suspension was filtered over *Celite*, diluted with Et₂O (200 ml), washed with 5% aq. HCl soln. (100 ml), H₂O (2 \times 80 ml), and brine (80 ml), dried (MgSO₄), and evaporated. FC (toluene/AcOEt 40 : 1 \rightarrow 15 : 1) gave **28** (1.89 g, 75%). White foam. *R*_f (toluene/AcOEt 18 : 1) 0.16. M.p. 47–55°. [α]_D²⁵ = +64.2 (*c* = 1.00, CH₂Cl₂). IR (CH₂Cl₂): 3595w, 3300w, 3031m, 2926m, 2870m, 1954w (*br.*), 1733w, 1700w, 1605m, 1496m, 1453m, 1363m, 1215m, 1154s, 1095s, 1028s, 911w, 811w. ¹H-NMR (500 MHz, CDCl₃, assignment based on a COSY spectrum): 7.41–7.01 (*m*, 105 arom. H); 5.68 (*d*, *J* = 3.5), 5.65 (*d*, *J* = 3.6), 5.64 (*d*, *J* = 3.6), 5.62 (*d*, *J* = 3.5), 5.60 (*d*, *J* = 3.8), 5.53 (*d*, *J* = 3.5) (H–C(1^{II-VII})); 5.00 (*d*, *J* = 11.5, ArCH); 4.95–4.75 (*m*, 8 ArCH); 4.74 (*dd*, *J* = 2.3, 5.8, H–C(6^I)); 4.73–4.61 (*m*, 7 ArCH); 4.50–4.33 (*m*, 25 ArCH); 4.30 (*d*, *J* = 12.2, ArCH); 4.11–3.96 (*m*, H–C(3^I), H–C(3^{II-VI}), H–C(4^I), H–C(4^{II-VI})); 3.95–3.82 (*m*, H–C(2^I), H–C(5^{II-VI}), H–C(6)); 3.79–3.70 (*m*, 5 H–C(6), H–C(3^{VII}), H–C(5^{VII})); 3.68–3.63 (*m*, H–C(4^{VII}), H–C(5^I), 1 H'–C(6)); 3.54–3.48 (*m*, H–C(2^{II-VI}), H–C(6^{VII}), 5 H'–C(6)); 3.41 (2*dd*, *J* = 3.6, 9.8, H–C(2^{VII}), H–C(6^{VII})); 2.64 (*d*, *J* = 2.3, C≡CH); 2.52 (*br. s*, OH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 139.01–137.72 (several *s*); 128.46–126.47 (several *d*); 96.73, 96.70, 96.28, 96.23 (2 C), 96.19 (5*d*, C(1^{II-VII})); 82.75 (*d*, C(4^I)); 81.80, 81.70, 81.67, 81.62, 81.50 (5*d*, C(3^{II-VI})); 81.39 (*d*, C(3^{VII})); 79.67, 79.57, 79.53, 79.43, 79.40 (5*d*, C(2^{II-VI})); 79.02 (*d*, C(2^{VII})); 78.75 (*d*, C(5^I)); 78.63 (*s*, C≡CH); 77.81 (*s*, C≡CH); 75.20, 74.54 (2*t*, 2 ArCH); 73.98, 73.69, 73.07, 72.57, 72.45, 72.30 (6*d*, C(3^I), C(4^{II-VI})); 73.86–72.72 (several *t*, 19 ArCH₂); 71.61 (*d*, C(4^{VII})); 70.84 (4 C); 70.75 (2 C) (2*d*, C(2^I), C(5^{II-VI})); 70.36 (*d*, C(5^{VII})); 69.83 (*t*, C(6^{VII})); 68.80, 68.70 (5 C)

(2*t*, C(1¹), C(6^{II-VI})); 66.38 (*d*, C(6¹)). MALDI-MS: 3091 ([*M* + *K*]⁺), 3074 ([*M* + *Na*]⁺). Anal. calc. for C₁₉₁H₁₉₈O₃₅ · 2 H₂O (3089.71): C 74.25, H 6.60; found: C 74.00, H 6.50.

2,3-Bis-O-(4-chlorobenzyl)- α -D-glucopyranosyl-[(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl)]₅-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**29**). Under Ar, **26** (1.4 g, 0.37 mmol) in a soln. of 1% I₂ in MeOH (66 ml) was stirred under reflux for 5 h. After evaporation, the crude was diluted with AcOEt (200 ml). The org. phase was washed with a sat. aq. Na₂S₂O₃ soln. (150 ml), H₂O (150 ml), and brine (1500 ml), dried (MgSO₄), and evaporated. FC (toluene/AcOEt 25 : 1 \rightarrow 4 : 1) gave **29** (800 mg, 60%). White foam. *R*_f (toluene/AcOEt 18 : 6) 0.31. [α]_D²⁵ = +64.2 (*c* = 0.95, CHCl₃). IR (CHCl₃): 3593w, 3303w, 2926m, 2869m, 1785w, 1600m, 1492m, 1463m, 1361m, 1261m, 1154s, 1090s, 1015s. ¹H-NMR (500 MHz, CDCl₃): 7.32–6.85 (*m*, 80 arom. H); 5.52 (*d*, *J* = 3.6, 2 H), 5.48 (*d*, *J* = 3.5), 5.47 (*d*, *J* = 3.3), 5.44 (*d*, *J* = 3.4), 5.43 (*d*, *J* = 3.5) (H–C(1^{II-VII})); 4.90 (*d*, *J* = 12.0, ArCH); 4.79 (*dd*, *J* = 2.3, 5.8, H–C(6¹)); 4.77 (*d*, *J* = 12.0), 4.75 (*d*, *J* = 12.5), 4.74 (*d*, *J* = 11.6), 4.72 (*d*, *J* = 11.8), 4.70 (*d*, *J* \approx 11.0), 4.68 (*d*, *J* = 10.5, 2 H), 4.64 (*d*, *J* = 11.8), 4.63 (*d*, *J* \approx 12.0, 2 H), 4.607 (*d*, *J* = 12.1), 4.599 (*d*, *J* \approx 11.0), 4.591 (*d*, *J* = 11.7), 4.58 (*d*, *J* \approx 12.3), 4.53 (*d*, *J* = 11.7), 4.47 (*d*, *J* = 12.2), 4.44 (*d*, *J* = 12.2) (17 ArCH); 4.42–4.28 (*m*, 22 ArCH); 4.04–3.99 (*m*, H–C(2¹)); 3.98–3.87 (*m*, H–C(1¹), H–C(3¹), H–C(4¹), H–C(3^{II-VI}), H–C(4^{II-VI}), H–C(3^{VII})); 3.81–3.77 (*m*, 4 H–C(5)); 3.72–3.60 (*m*, H¹–C(1¹), H–C(5¹), 2 H–C(5), H–C(6^{II-VI}), 2 H–C(6^{VII})); 3.53 (*dt*, *J* = 2.8, 8.9, H–C(4^{VII})); 3.47–3.41 (*m*, H–C(2^{II-VI}), H¹–C(6^{II-VI})); 3.32 (*dd*, *J* = 3.6, 9.7, H–C(2^{VII})); 2.67 (*d*, *J* = 2.3, C \equiv CH); 2.39 (*d*, *J* = 3.0, HO–C(4^{VII})); 1.81 (*br. t*, *J* = 6.5, HO–C(6^{VII})). ¹³C-NMR (125 MHz, CDCl₃): 137.26–135.89 (several *s*); 133.96–133.01 (several *s*); 129.61–127.33 (several *d*); 97.03 (2 *C*); 96.63, 96.58, 96.50, 96.43 (5*d*, C(1^{II-VII})); 82.47 (*d*, C(4¹)); 81.43 (2 *C*), 81.36 (2 *C*), 81.25 (2 *C*) (3*d*, C(3^{II-VI})); 79.63, 79.59, 79.45 (2 *C*), 79.39, 79.24 (5*d*, C(2^{II-VII})); 78.86 (*d*, C(5¹)); 78.16 (*br. s*, C \equiv CH); 74.03, 73.62, 73.46, 73.17, 73.02 (2 *C*) (5*d*, C(3¹), C(4^{II-VI})); 74.33–72.10 (several *t*, 20 ArCH₂); 71.84 (*d*, C(4^{VII})); 70.99 (2 *C*), 70.95 (2 *C*), 70.91 (2 *C*), 70.82 (4*d*, C(2¹), C(5^{II-VI})); 68.97, 68.91, 68.86, 68.79 (2 *C*), 68.64 (5*t*, C(1¹), C(6^{II-VI})); 66.11 (*d*, C(6¹)); 62.49 (*t*, C(6^{VII})). MALDI-MS: 3675.4 ([*M* + *Na*]⁺). Anal. calc. for C₁₈₄H₁₇₂Cl₂₀O₃₅ · H₂O (3652.42): C 60.21, H 4.77, Cl 19.41; found: C 60.11, H 5.03, Cl 19.74.

[(1 \rightarrow 4)-(2,3,6-Tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl)]₅-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**30**). A mixture of **29** (160 mg, 0.044 mmol) and (Bu₃Sn)₂O (13 μ l, 0.033 mmol) in toluene (5 ml) was stirred under reflux with azeotropic removal of H₂O for 4 h. Toluene (3 ml) was distilled off. The residual soln. was treated with 4-ClC₆H₄CH₂Cl (14 mg, 0.087 mmol) and Bu₄NI (16 mg, 0.044 mmol), and was stirred for 16 h at 90°. After evaporation *in vacuo*, a soln. of the residue in AcOEt (10 ml) was stirred with aq. KF for 1 h. After separation, the org. layer was dried (MgSO₄) and evaporated. FC (toluene/AcOEt 25 : 1 \rightarrow 9 : 2) gave **30** (110 mg, 67%). White foam. *R*_f (toluene/AcOEt 18 : 2) 0.35. [α]_D²⁵ = 59.4 (*c* = 1.0, CHCl₃). IR (CHCl₃): 3590w, 3303w, 2925m, 2869m, 1600m, 1492m, 1361m, 1154s, 1090s, 1015s. ¹H-NMR (500 MHz, CDCl₃): 7.32–6.84 (*m*, 84 arom. H); 5.52 (*d*, *J* = 3.6, 2 H), 5.49 (*d*, *J* = 3.4), 5.48 (*d*, *J* = 3.6, 2 H), 5.44 (*d*, *J* = 3.6) (H–C(1^{II-VII})); 4.90 (*d*, *J* = 11.8, ArCH); 4.79 (*dd*, *J* = 2.3, 5.7, H–C(6¹)); 4.78 (*d*, *J* = 12.0), 4.74 (*d*, *J* = 10.8), 4.73 (*d*, *J* = 11.0), 4.72 (*d*, *J* = 12.0), 4.71 (*d*, *J* = 12.1), 4.69 (*d*, *J* = 12.4), 4.68 (*d*, *J* = 12.1), 4.67 (*d*, *J* = 11.7), 4.65 (*d*, *J* \approx 12.0), 4.62 (*d*, *J* = 12.0, 2 H), 4.60 (*d*, *J* = 11.8), 4.59 (*d*, *J* = 12.0), 4.55 (*d*, *J* \approx 12.0), 4.52 (*d*, *J* = 11.7), 4.50 (*d*, *J* = 12.5), 4.48 (*d*, *J* = 12.2), 4.47 (*d*, *J* = 12.2), 4.45 (*d*, *J* = 11.1), 4.44 (*d*, *J* = 12.3), 4.43 (*d*, *J* = 12.2) (21 ArCH); 4.40–4.27 (*m*, 21 ArCH); 4.05–4.02 (*m*, H–C(2¹)); 4.00–3.85 (*m*, H–C(1¹), H–C(3¹), H–C(4¹), H–C(3^{II-VII}), H–C(4^{II-VI})); 3.82–3.77 (*m*, H–C(5^{II-VI})); 3.72–3.60 (*m*, H¹–C(1¹), H–C(5¹), H–C(6^{II-VI}), H–C(5^{VII}), 2 H–C(6^{VII})); 3.49 (*dd*, *J* = 3.7, 9.9, H–C(2)); 3.48–3.39 (*m*, 4 H–C(2), H¹–C(6^{II-VI}), H–C(4^{VII})); 3.37 (*dd*, *J* = 3.6, 9.6, H–C(2)); 2.67 (*d*, *J* = 2.3, C \equiv CH); 2.55 (*d*, *J* = 2.4, OH). ¹³C-NMR (125 MHz, CDCl₃): 137.31–135.42 (several *s*); 133.93–132.99 (several *s*); 131.23–125.28 (several *d*); 97.11, 96.62, 96.57 (2 *C*), 96.42 (2 *C*) (4*d*, C(1^{II-VII})); 82.44 (*d*, C(4¹)); 81.47, 81.33 (2 *C*); 81.22 (3 *C*) (3*d*, C(3^{II-VI})); 79.56 (2 *C*), 79.46, 79.36, 78.93 (2 *C*) (4*d*, C(2^{II-VII})); 78.84 (*d*, C(5¹)); 78.14 (*br. s*, C \equiv CH); 74.03, 73.64, 73.59, 73.46, 73.10, 73.05 (6*d*, C(3¹), C(4^{II-VI})); 74.36–72.07 (several *t*, 21 ArCH₂); 71.88 (*d*, C(4^{VII})); 70.92 (3 *C*), 70.87, 70.80, 70.44, 70.02 (4*d*, C(2¹), C(5^{II-VI})); 70.01 (*t*, C(6^{VII})); 68.95, 68.84 (2 *C*), 68.77 (3 *C*) (3*t*, C(1¹), C(6^{II-VI})); 66.09 (*d*, C(6¹)). MALDI-MS: 3801.1 ([*M* + *Na*]⁺), 3817.0 ([*M* + *K*]⁺).

6-O-Benzyl-2,3-bis-O-(4-chlorobenzyl)- α -D-glucopyranosyl-[(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl)]₅-(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- β -D-glucopyranosyl)-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**31**). Under Ar, a soln. of **27** (2.5 g, 0.66 mmol) in dry CH₂Cl₂ (110 ml) was stirred at –40° for 10 min, treated with Et₃SiH (2.1 ml, 13.36 mmol), and BF₃ · Et₂O (0.84 ml, 6.68 mmol), and stirred for 1 h at –40° and for 24 h at –10°. The soln. was washed with sat. aq. NaHCO₃ soln. (70 ml), H₂O (70 ml), and brine (70 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 50 : 1 \rightarrow 5 : 1) gave **31** (1.9 g, 76%). White foam. *R*_f (toluene/AcOEt 18 : 2) 0.35. [α]_D²⁵ = +55.2 (*c* = 1.00, CHCl₃). IR (CHCl₃): 3608w, 3304w, 2927m, 2869m, 1600m, 1492m, 1408m, 1361m, 1090s, 1039s, 1017s. ¹H-NMR

(500 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 7.32–6.85 (*m*, 84 arom. H); 5.51 (*d*, *J* = 3.5), 5.48 (*d*, *J* = 3.4), 5.38 (*d*, *J* = 3.5) (H–C(1^{III-VII})); 4.96 (*d*, *J* = 12.0, ArCH); 4.75 (*d*, *J* = 10.9, ArCH), 4.74 (*dd*, *J* = 3.4, 5.8, H–C(6^I)); 4.73 (*d*, *J* = 10.9, ArCH); 4.72–4.58 (*m*, 15 ArCH); 4.51 (*d*, *J* = 11.4), 4.44 (*d*, *J* = 12.0), 4.43 (*d*, *J* = 12.1) (3 ArCH); 4.38–4.30 (*m*, 20 ArCH, H–C(1^{II})); 4.23 (*d*, *J* = 12.1, ArCH); 4.00–3.86 (*m*, H–C(3^I), H–C(3^{III-VII}), H–C(4^{II-VI}), 1 H–C(5)); 3.83–3.76 (*m*, H–C(1^I), H–C(2^I), 3 H–C(5)); 3.76–3.66 (*m*, H–C(4^I), H–C(5^{VII}), 6 H–C(6)); 3.64 (*t*, *J* = 9.4, H–C(4^{VII})); 3.56–3.48 (*m*, H'–C(1^I), H–C(5^I), 1 H–C(6), H–C(6^{II})); 3.47–3.41 (*m*, H–C(2^{III-VI}), H–C(3^{II}), 3 H–C(6), H'–C(6^{II})); 3.36 (*dd*, *J* = 3.5, 9.7, H–C(2^{VII})); 3.31 (*t*, *J* = 8.8, H–C(2^{II})); 3.20 (*br. ddd*, *J* ≈ 1.5, 3.5, 9.3, H–C(5^{VII})); 2.65 (*br. s*, *J* = 2.3, OH); 2.62 (*d*, *J* = 2.3, C≡CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HSQC.GRASP spectrum): 137.77–135.95 (several *s*); 133.79–132.87 (several *s*); 129.51–127.35 (several *d*); 102.15 (*d*, C(1^{II})); 97.18, 96.85, 96.64, 96.60, 96.45 (5*d*, C(1^{III-VII})); 84.67 (*d*, C(3^{II})); 82.34 (*d*, C(2^{II})); 81.49, 81.35 (2 *C*), 81.22 (2 *C*) (3*d*, C(3^{III-VII})); 81.00 (*d*, C(4^I)); 79.56 (2 *C*), 79.50, 79.39 (3*d*, C(2^{III-VI})); 78.88 (*d*, C(2^{VII})); 78.14 (*s*, C≡CH); 78.07 (*d*, C(5^I)); 77.77 (*s*, C≡CH); 75.90, 75.05 (2*d*, C(3^I), C(4^{II})); 74.97 (*d*, C(5^{II})); 73.77 (*d*, C(2^I)); 73.65, 73.46, 73.25, 73.05 (4*d*, C(4^{III-VI})); 74.42–72.34 (several *t*, 21 ArCH₂); 70.95 (4 *C*) (*d*, C(5^{III-VI})); 70.39 (*d*, C(5^{VII})); 70.15 (*t*, C(6^{II})); 69.06 (3 *C*), 68.82 (2 *C*) (2*t*, C(6^{III-VII})); 67.91 (*t*, C(1^I)); 66.61 (*d*, C(6^I)). MALDI-MS: 3766 ([*M* + Na]⁺). Anal. calc. for C₁₉₁H₁₇₈Cl₂₀O₃₅ (3742.54): C 61.30, H 4.79; found: C 61.30, H 4.79.

Glycosidation of 13 by 28. Under Ar, a suspension of **13** (243 mg, 0.48 mmol), **28** (590 mg, 0.19 mmol), and 3-Å molecular sieves (500 mg) in dry toluene (60 ml) was stirred at –45° for 1 h, treated with NIS (780 mg, 0.35 mmol) and TfOH (8.5 μl, 0.096 mmol) and stirred for 20 h. The suspension was filtered over *Celite*, diluted with Et₂O (100 ml), washed with 10% aq. Na₂O₃ soln. (40 ml), sat. aq. NaHCO₃ soln. (2 × 30 ml), H₂O (2 × 30 ml), and brine (30 ml), dried (MgSO₄), and evaporated. FC (silica H, toluene/AcOEt 40 : 1 → 30 : 1) gave **32** (289 mg, 49%) and **33** (112 mg, 19%).

6-O-Acetyl-2,3-di-O-benzyl-4-deoxy-4-C-ethynyl-α-D-glucopyranosyl-[(1 → 4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)]₆-(1 → 3)-2,6-anhydro-1,4,5-tri-O-benzyl-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (32). White foam. R_f (toluene/AcOEt 17:1) 0.32. M.p. 52–55°. [α]_D²⁵ = +86.4 (*c* = 1.00, CH₂Cl₂). IR (CH₂Cl₂): 3301*m*, 2925*m*, 2870*m*, 1955*w* (*br.*), 1740*m*, 1605*m*, 1496*m*, 1454*m*, 1364*m*, 1237*m*, 1209*m*, 1154*s*, 1095*s*, 1028*s*, 913*w*. ¹H-NMR (500 MHz, CDCl₃, assignment based on COSY spectra): 7.46–7.01 (*m*, 115 arom. H); 5.66 (*d*, *J* = 3.5), 5.65 (*d*, *J* = 4.0), 5.65 (*d*, *J* = 3.4), 5.64 (*d*, *J* = 3.2, 2 H), 5.62 (*d*, *J* = 3.7), 5.53 (*d*, *J* = 3.5) (H–C(1^{II-VIII})); 5.06–4.68 (*m*, 19 ArCH); 4.67–4.47 (*m*, 27 ArCH, H–C(6^I)); 4.22 (*dd*, *J* = 3.9, 12.1, H–C(6^{VIII})); 4.12–3.97 (*m*, 17 H); 3.95–3.82 (*m*, 8 H); 3.80–3.70 (*m*, 5 H); 3.69–3.61 (*m*, 3 H); 3.55–3.48 (*m*, 12 H); 3.31 (*dd*, *J* = 3.5, 9.5, H–C(2)); 2.67 (*dt*, *J* = 2.3, 10.7, H–C(4^{VIII})); 2.64 (*d*, *J* = 2.3, H–C(8^I)); 2.18 (*d*, *J* = 2.3, C≡CH); 1.97 (*s*, AcO). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 170.64 (*s*, C=O); 139.14–137.20 (several *s*); 128.47–126.44 (several *d*); 97.00 (2 *C*), 96.71, 96.42, 96.23, 96.17 (2 *C*) (5*d*, C(1^{II-VIII})); 82.75 (*d*, C(4^I)); 81.69 (2 *C*), 81.62 (2 *C*), 81.51, 81.26 (4*d*, C(3^{II-VII})); 80.02 (*s*, C≡CH); 79.59, 79.54 (2 *C*), 79.50 (2 *C*), 79.42, 78.94, 78.76 (5*d*, C(5^I), C(2^{II-VIII})); 78.64 (*d*, C(8^I)); 77.82 (*s*, C(7^I)); 75.74, 75.45 (2*t*, 2 ArCH₂); 73.99, 73.81, 73.08, 72.91 (2 *C*), 72.88 (2 *C*), 72.85 (6*d*, C(4^{II-VIII})); 73.76–72.01 (several *t*, 21 ArCH₂); 72.04 (*s*, C≡CH); 70.84 (4 *C*), 70.76 (3 *C*) (2*d*, C(2^I), C(5^{II-VII})); 69.18 (C(5^{VIII})); 68.68 (7 *C*) (*t*, C(1^I), C(6^{II-VII})); 66.38 (*d*, C(6^I)); 64.00 (*t*, C(6^{VIII})); 36.71 (*d*, C(4^{VIII})); 20.80 (*q*, Me). MALDI-MS: 3485 ([*M* + K]⁺), 3466 ([*M* + Na]⁺). Anal. calc. for C₂₁₅H₂₂₂O₄₀ (3446.09): C 74.94, H 6.49; found: C 74.91, H 6.62.

6-O-Acetyl-2,3-di-O-benzyl-4-deoxy-4-C-ethynyl-β-D-glucopyranosyl-[(1 → 4)-(2,3,6-tri-O-benzyl-α-D-glucopyranosyl)]₆-(1 → 3)-1,4,5-tri-O-benzyl-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (33). R_f (toluene/AcOEt 17:1) 0.29. M.p. 54–56°. [α]_D²⁵ = +84.2 (*c* = 1.00, CH₂Cl₂). IR (CH₂Cl₂): 3301*m*, 3088*m*, 3031*m*, 2924*m*, 2870*m*, 1736*m*, 1605*m*, 1496*m*, 1454*m*, 1364*m*, 1209*m*, 1154*s*, 1094*s*, 1028*s*, 912*w*. ¹H-NMR (500 MHz, CDCl₃, assignment based on COSY spectra): 7.54–6.98 (*m*, 115 arom. H); 5.80 (*d*, *J* = 3.9), 5.66 (*d*, *J* = 3.7), 5.64 (*d*, *J* = 3.6), 5.62 (*d*, *J* = 3.6), 5.56 (*d*, *J* = 3.5), 5.53 (*d*, *J* = 3.5) (H–C(1^{II-VIII})); 5.05–4.22 (*m*, 48 PhCH, C(6^I), C(1^{VIII})); 4.21–4.18 (*m*, H–C(6^{VIII})); 4.12–3.82 (*m*, 22 H); 3.80–3.59 (*m*, 9 H); 3.55–3.43 (*m*, 12 H); 3.30–3.19 (*m*, 2 H); 3.09 (*t*, *J* = 8.1, H–C(4)); 2.64 (*d*, *J* = 2.3, H–C(8^I)); 2.53 (*dt*, *J* = 2.4, 10.5, H–C(4^{VIII})); 2.18 (*d*, *J* = 2.3, C≡CH), 1.86 (*s*, AcO). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 170.83 (*s*, C=O); 139.51–137.73 (several *s*); 128.86–126.52 (several *d*); 102.27 (*d*, C(1^{VIII})); 96.99, 96.71, 96.23, 96.16 (2 *C*), 96.00 (5*d*, C(1^{II-VII})); 82.76 (*d*, C(4^I)); 82.19, 81.93, 81.89, 81.68, 81.64 (2 *C*), 81.51 (6*d*, C(3^{II-VIII})); 80.42 (*d*, C≡CH); 79.96, 79.53 (2 *C*), 78.76, 78.16 (2 *C*), 77.82 (2 *C*) (5*d*, C(5^I), C(2^{II-VIII})); 78.64 (*s*, C(8^I)); 77.83 (*d*, C(7^I)); 75.73–72.23 (several *t*, 23 ArCH₂); 73.91 (2 *C*), 73.84 (2 *C*), 73.22, 73.09 (2 *C*), 72.88 (5*d*, C(4^I), C(3^{II-VIII})); 71.17 (2 *C*), 70.82 (3 *C*), 70.65 (2 *C*) (3*d*, C(2^I), C(5^{II-VII})); 68.92 (2 *C*), 68.70 (3 *C*), 68.61 (2 *C*) (3*t*, C(1^I), C(6^{II-VII})); 67.60 (*d*, C(6^I)); 66.39 (*d*, C(5^{VIII})); 64.29 (*t*, C(6^{VIII})); 36.89 (*d*, C(4^{VIII})); 20.68 (*q*, Me). MALDI-MS: 3485 ([*M* + K]⁺), 3468 ([*M* + Na]⁺). Anal. calc. for C₂₁₅H₂₂₂O₄₀ (3446.09): C 74.94, H 6.49; found: C 74.36, H 6.48.

Glycosidation of 15 with 30. Under Ar, a suspension of **30** (470 mg, 0.125 mmol), **15** (174 mg, 0.25 mmol), and 3-Å molecular sieves (500 mg) in dry toluene (20 ml) was stirred at -60° for 1 h, treated with NIS (51 mg, 0.22 mmol) and TfOH (5.5 μ l, 0.06 mmol), and stirred for 20 h. The suspension was filtered over *Celite*. The filtrate was diluted with Et₂O (40 ml), washed with 10% aq. Na₂S₂O₃ soln. (40 ml), sat. aq. NaHCO₃ soln. (2 \times 30 ml), H₂O (2 \times 30 ml), and brine (30 ml), dried (MgSO₄), and evaporated. FC (silica H, toluene/AcOEt 60:1 \rightarrow 30:1) gave **34** (260 mg, 48%) and **35** (190 mg, 36%).

*2,3,6-Tris-O-(4-chlorobenzyl)-4-deoxy-4-C-ethynyl- α -D-glucopyranosyl-[(1 \rightarrow 4)-2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**34**).* White foam. R_f (toluene/AcOEt 9:1) 0.62. $[\alpha]_D^{25} = +64.7$ ($c = 1.00$, CHCl₃). IR (CHCl₃): 3304w, 2922m, 1599m, 1492m, 1404m, 1360m, 1150s, 1090s, 1037s. ¹H-NMR (500 MHz, CDCl₃): 7.31–6.86 (*m*, 96 arom. H); 5.57 (*d*, $J = 3.5$), 5.55–5.54 (*m*, 3 H), 5.50 (*d*, $J = 3.5$), 5.48 (*d*, $J = 3.7$), 5.46 (*d*, $J = 3.5$) (H–C(1^{II-VIII})); 4.90 (*d*, $J = 11.9$), 4.89 (*d*, $J = 12.4$), 4.87 (*d*, $J = 10.8$) (3 ArCH); 4.81 (*dd*, $J = 2.3$, 5.8, H–C(6^I)); 4.75 (*d*, $J = 11.9$, ArCH); 4.72–4.58 (*m*, 15 ArCH); 4.55–4.44 (*m*, 5 ArCH); 4.40–4.27 (*m*, 22 ArCH); 4.08–3.88 (*m*, 18 H); 3.86–3.78 (*m*, 8 H); 3.75–3.61 (*m*, 8 H); 3.56 (*dd*, $J = 3.6$, 9.3, H–C(2)); 3.49–3.37 (*m*, 13 H); 3.32 (*dd*, $J = 3.5$, 9.6, H–C(2)); 2.83 (*dt*, $J = 2.9$, 8.1, H–C(4^{VIII})); 2.69 (*d*, $J = 2.3$, H–C(8^I)); 2.17 (*d*, $J = 2.3$, C \equiv CH). ¹³C-NMR (125 MHz, CDCl₃): 137.26–135.44 (several *s*); 133.95–133.01 (several *s*); 129.79–127.31 (several *d*); 97.58, 96.58 (2 C), 96.41 (2 C), 96.35, 96.31 (5d, C(1^{II-VIII})); 82.46 (*d*, C(4^I)); 81.54, 81.47, 81.38 (4 C), 81.22 (4d, C(3^{II-VIII})); 81.22 (*s*, C \equiv CH); 79.63 (2 C), 79.49 (3 C), 79.36, 79.16 (4d, C(2^{II-VIII})); 78.86 (*d*, C(5^I)); 78.16 (*br. s*, C(8^I), C(7^I)); 74.61 (*t*, ArCH); 74.03, 73.61 (2 C), 73.56 (2 C), 73.01, 72.87 (5d, C(3^I), C(4^{II-VII})); 72.77–72.23 (several *t*, 23 ArCH₂); 72.09 (*s*, C \equiv CH); 70.99, 70.90 (6 C), 70.82 (3d, C(2^I), C(5^{II-VIII})); 69.33, 68.97 (3 C), 68.86 (3 C), 68.56 (4t, C(1^I), C(6^{II-VIII})); 66.11 (*d*, C(6^I)); 36.54 (*d*, C(4^{VIII})). MALDI-MS: 4346.2 ($[M + Na]^+$). Anal. calc. for C₂₂₀H₂₀₂Cl₂₄O₃₉ (4320.86): C 61.15, H 4.71; found: C 61.31, H 4.83.

*2,3,6-Tris-O-(4-chlorobenzyl)-4-deoxy-4-C-ethynyl- β -D-glucopyranosyl-[(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-1,4,5-tris-O-(4-chlorobenzyl)-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-oct-7-ynitol (**35**).* White foam. R_f (toluene/AcOEt 9:1) 0.58. $[\alpha]_D^{25} = +55.7$ ($c = 1.00$, CHCl₃). IR (CHCl₃): 3301w, 2925m, 2870m, 1599m, 1492m, 1360m, 1090s. ¹H-NMR (500 MHz, CDCl₃, assignment based on a HSQC-GRASP spectrum): 7.32–6.83 (*m*, 96 arom. H); 5.66 (*d*, $J = 3.9$), 5.52 (*d*, $J = 3.6$, 2 H), 5.48 (*d*, $J = 3.6$), 5.45 (*d*, $J = 3.5$), 5.43 (*d*, $J = 3.5$) (H–C(1^{II-VIII})); 4.97 (*d*, $J = 11.4$), 4.90 (*d*, $J = 11.3$, 2 H) (3 ArCH); 4.79 (*dd*, $J = 2.3$, 5.8, H–C(6^I)); 4.78 (*d*, $J = 13.0$), 4.73 (*d*, $J = 12.0$), 4.72 (*d*, $J = 12.0$), 4.69 (*d*, $J = 12.1$), 4.65 (*d*, $J = 11.8$), 4.64 (*d*, $J = 12.1$), 4.63 (*d*, $J = 10.9$, 2 H), 4.60 (*d*, $J = 11.9$), 4.59 (*d*, $J = 12.5$, 2 H), 4.56 (*d*, $J = 12.4$, 2 H), 4.55 (*d*, $J = 11.3$), 4.53 (*d*, $J = 11.7$, 2 H), 4.50 (*d*, $J = 10.3$) (17 ArCH); 4.48–4.42 (*m*, 3 ArCH); 4.39–4.29 (*m*, 21 ArCH); 4.28 (*d*, $J = 12.5$, ArCH); 4.22 (*d*, $J = 8.0$, H–C(1^{VIII})); 4.18 (*d*, $J = 13.5$), 4.06 (*d*, $J = 12.2$), 4.02 (*d*, $J = 11.9$) (3 ArCH); 4.04 (*t*, $J \approx 9.0$, H–C(3^I)); 3.98–3.84 (*m*, H–C(3^{II-VI}), H–C(4^I), H–C(4^{II-VII}), H–C(2^I), H–C(1^I)); 3.80–3.73 (*m*, 5 H–C(5), H–C(3^{VII}), H–C(6^{VII})); 3.69–3.60 (*m*, H–C(5^I), 1 H–C(5), H–C(1^I), 4 H–C(6), H–C(6^{VIII})); 3.48–3.35 (*m*, 4 H–C(2), H–C(2^{VII}), 6 H–C(6), H–C(6^{VII})); 3.30–3.24 (*m*, H–C(2), H–C(5^{VIII}), H–C(6^{VIII})); 3.20 (*t*, $J = 8.7$, H–C(3^{VIII})); 3.10 (*t*, $J = 8.6$, H–C(2^{VIII})); 2.67 (*d*, $J = 2.3$, H–C(8^I)); 2.64 (*dt*, $J = 2.3$, 10.4, H–C(4^{VIII})); 2.18 (*d*, $J = 2.3$, C \equiv CH). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC-GRASP spectrum): 137.45–135.85 (several *s*); 133.94–132.97 (several *s*); 129.82–125.29 (several *d*); 102.32 (*d*, C(1^{VIII})); 97.17, 96.58 (2 C), 96.43 (2 C), 96.35 (4d, C(1^{II-VIII})); 82.77 (*d*, C(3^{VIII})); 82.46 (*d*, C(4^I)); 82.08 (*d*, C(2^{VIII})); 81.39 (*s*, C \equiv CH), 81.60, 81.37, 81.25, 81.22 (2 C) (4d, C(3^{II-VI})); 80.36 (*d*, C(3^{VII})); 79.74, 79.58 (2 C), 79.48, 79.39 (4d, C(2^{II-VI})); 78.85 (*d*, C(5^I)); 78.44 (*d*, C(2^{VII})); 78.15 (*br. s*, C \equiv CH); 76.19 (*d*, C(4^{VII})); 75.11 (*d*, C(5^{VIII})); 74.00, 73.54, 73.35, 73.16, 73.02 (2 C) (5d, C(3^I), C(4^{II-VI})); 75.01–72.00 (several *t*, 24 ArCH₂); 72.09 (*s*, C \equiv CH); 71.21, 70.96 (2 C), 70.87 (2 C), 70.80 (2 C) (4d, C(2^I), C(5^{II-VII})); 70.06 (*t*, C(6^{VII})); 68.95 (3 C), 68.83 (2 C), 68.76 (3t, C(1^I), C(6^{II-VI})); 67.47 (*t*, C(6^{VIII})); 66.11 (*d*, C(6^I)); 36.95 (*d*, C(4^{VIII})). MALDI-MS: 4349 ($[M + Na]^+$). Anal. calc. for C₂₂₀H₂₀₂Cl₂₄O₃₉ (4320.86): C 61.15, H 4.71; found: C 61.38, H 4.90.

Glycosylation of 15 with 31. Under Ar, a suspension of **31** (3.5 g, 0.93 mmol), **15** (1.3 g, 1.87 mmol), and 3-Å molecular sieves (4 g) in dry toluene (150 ml) was stirred at -60° for 1 h, treated with NIS (379 mg, 0.168 mmol) and TfOH (41 μ l, 0.46 mmol), and stirred for 2 h. The suspension was filtered over *Celite*. The filtrate was diluted with Et₂O (100 ml), washed with 10% aq. Na₂S₂O₃ soln. (100 ml), sat. aq. NaHCO₃ soln. (2 \times 100 ml), H₂O (2 \times 100 ml), and brine (100 ml), dried (MgSO₄), and evaporated. FC (silica H, toluene/AcOEt 60:1 \rightarrow 30:1) gave **36** (1.65 g, 41%) and **37** (1.8 g, 45%).

2,3,6-Tris-O-(4-chlorobenzyl)-4-deoxy-4-C-ethynyl- α -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzyl-2,3-bis-O-(4-chlorobenzyl)- α -D-glucopyranosyl-[(1 \rightarrow 4)-(2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl]₄-(1 \rightarrow 4)-2,3,6-tris-O-(4-chlorobenzyl)- β -D-glucopyranosyl-(1 \rightarrow 3)-2,6-anhydro-1,4,5-tris-O-(4-chlorobenzyl)-7,8-dideoxy-D-

glycero-L-gulo-*oct-7-ynitol* (**36**). White foam. R_f (toluene/AcOEt 18:2) 0.44. $[\alpha]_D^{25} = +56.3$ ($c = 1.00$, CHCl_3). IR (CHCl_3): 3305w, 2927m, 2868m, 1599m, 1492m, 1408m, 1360m, 1090s, 1036s, 1015s. $^1\text{H-NMR}$ (500 MHz, CDCl_3 , assignment based on a HSQC-GRASP spectrum): 7.32–6.85 (*m*, 97 arom. H); 5.56 (*d*, $J = 3.5$), 5.53 (*d*, $J = 3.2$), 5.52 (*d*, $J = 3.0$), 5.50 (*d*, $J = 3.5$), 5.46 (*d*, $J = 3.5$), 5.39 (*d*, $J = 3.5$) (H–C(1^{III-VIII})); 4.96 (*d*, $J = 12.0$), 4.89 (*d*, $J = 10.8$), 4.76 (*d*, $J = 11.5$), 4.75 (*d*, $J = 11.5$) (4 ArCH); 4.74 (*dd*, $J = 2.2$, 6.0, H–C(6^I)); 4.71 (*d*, $J = 11.8$, ArCH), 4.69–4.55 (*m*, 15 ArCH), 4.52 (*d*, $J = 11.5$), 4.47 (*d*, $J = 12.4$), 4.45 (*d*, $J = 12.1$), 4.44 (*d*, $J = 11.7$) (4 ArCH); 4.42–4.29 (*m*, 23 ArCH, H–C(1^{II})), 4.24 (*d*, $J = 12.1$, ArCH); 4.01–3.79 (*m*, H–C(1^I), H–C(2^I), H–C(3^I), H–C(3^{III-VIII}), H–C(4^{II-VII}), H–C(5^{III-VIII})); 3.75 (*t*, $J = 9.2$, H–C(4^I)); 3.73–3.66 (*m*, H–C(6^{II-VIII})); 3.56–3.39 (*m*, H⁺–C(1^I), H–C(5^I), H–C(3^{II}), H–C(2^{III-VII}), H⁺–C(6^{II-VIII})); 3.32 (*t*, $J = 9.5$, H–C(2^{II})); 3.31 (*dd*, $J = 3.6$, 9.6, H–C(2^{VIII})); 3.25 (*ddd*, $J = 1.5$, 3.5, 9.5, H–C(5^{II})); 2.83 (*dt*, $J = 2.1$, 10.6, H–C(4^{VIII})); 2.62 (*d*, $J = 2.2$, H–C(8^I)); 2.14 (*d*, $J = 2.2$, C≡CH). $^{13}\text{C-NMR}$ (125 MHz, CDCl_3 , assignment based on a HSQC-GRASP spectrum): 137.93–135.91 (several *s*); 133.79–132.86 (several *s*); 129.50–127.29 (several *d*); 102.15 (*d*, C(1^{II})); 97.54, 96.82, 96.67, 96.50, 96.40, 96.33 (*6d*, C(1^{III-VIII})); 84.67 (*d*, C(3^{II})); 82.33 (*d*, C(2^{II})); 81.58 (*s*, C≡CH); 81.48, 81.40, 81.30 (2 C), 81.25 (4*d*, C(3^{III-VIII})); 81.00 (*d*, C(4^I)); 79.58 (2 C), 79.51, 79.46, 79.40, 79.27 (5*d*, C(2^{III-VIII})); 79.20 (*d*, C(3^{VIII})); 78.07 (*d*, C(5^I)); 78.14 (*s*, C(8^I)); 77.76 (*s*, C(7^I)); 75.89, 74.98 (2*d*, C(3^I), C(4^{II})); 74.98 (*d*, C(5^{II})); 73.77 (*d*, C(2^I)); 73.62, 73.42, 73.00, 72.70, 72.80 (5*d*, C(4^{III-VII})); 74.74–72.30 (several *t*, 24 ArCH₂); 72.00 (*s*, C≡CH); 71.00 (2 C), 70.97, 70.93 (3 C) (3*d*, C(5^{III-VIII})); 69.35 (2 C), 69.05 (3 C), 68.92 (2 C) (3*t*, C(6^{II-VIII})); 67.91 (*t*, C(1^I)); 66.10 (*d*, C(6^I)); 36.54 (*d*, C(4^{VIII})). MALDI-MS: 4306 ($[M + \text{Na}]^+$). Anal. calc. for $\text{C}_{220}\text{H}_{203}\text{Cl}_{23}\text{O}_{39}$ (4286.41): C 61.55, H 4.77; found: C 61.41, H 4.84.

2,3,6-*Tris-O-(4-chlorobenzyl)-4-deoxy-4-C-ethynyl-β-D-glucopyranosyl-(1 → 4)-6-O-benzyl-2,3-bis-O-(4-chlorobenzyl)-α-D-glucopyranosyl-[(1 → 4)-2,3,6-tris-O-(4-chlorobenzyl)-α-D-glucopyranosyl]_r-(1 → 4)-2,3,6-tris-O-(4-chlorobenzyl)-β-D-glucopyranosyl-(1 → 3)-1,4,5-tris-O-(4-chlorobenzyl)-2,6-anhydro-7,8-dideoxy-D-glycero-L-gulo-*oct-7-ynitol* (**37**). R_f (toluene/AcOEt 9:1) 0.43. $[\alpha]_D^{25} = 52.7$ ($c = 1.00$, CHCl_3). IR (CHCl_3): 3305w, 2925m, 2867m, 1599m, 1492m, 1361m, 1090s, 1035s, 1015s. $^1\text{H-NMR}$ (500 MHz, CDCl_3 , assignment based on a HSQC-GRASP spectrum): 7.35–6.84 (*m*, 97 arom. H); 5.64 (*d*, $J = 3.8$), 5.56 (*d*, $J = 3.5$), 5.51 (*d*, $J = 3.6$), 5.49 (*d*, $J = 3.6$), 5.43 (*d*, $J = 3.5$) (H–C(1^{III-VII})); 4.96 (*d*, $J = 11.4$), 4.83 (*d*, $J = 11.0$), 4.77 (*d*, $J = 12.1$) (3 ArCH); 4.73 (*dd*, $J = 2.3$, 5.8, H–C(6^I)); 4.72–4.58 (*m*, 10 ArCH); 4.55–4.42 (*m*, 13 ArCH); 4.38–4.22 (*m*, 19 ArCH, H–C(1^{II}), H–C(1^{VIII})); 4.24 (*d*, $J = 12.7$), 4.16 (*d*, $J = 12.1$), 4.13 (*d*, $J = 12.1$) (3 ArCH); 4.20–3.78 (*m*, H–C(1^I), H–C(2^I), H–C(3^I), H–C(3^{III-VII}), H–C(4^{II-VII}), 4 H–C(5)); 3.76–3.62 (*m*, H–C(3^{VIII}), H–C(4^I), H–C(5^{VIII}), H–C(6^{II-VIII})); 3.56–3.33 (*m*, H⁺–C(1^I), H–C(2^{II-VII}), H–C(3^{II}), H–C(5^I), H⁺–C(6^{II-VIII})); 3.32–3.25 (*m*, H–C(2^{II}), H–C(5^{II}), H⁺–C(6^{VIII})); 3.09 (*t*, $J = 8.6$, H–C(2^{VII})); 2.63 (*dt*, $J = 2.3$, 10.3, H–C(4^{VIII})); 2.62 (*d*, $J = 2.2$, H–C(8^I)); 2.16 (*d*, $J = 2.3$, C≡CH). $^{13}\text{C-NMR}$ (125 MHz, CDCl_3 , assignment based on a HMQC spectrum): 137.93–135.91 (several *s*); 133.79–132.87 (several *s*); 129.50–127.29 (several *d*); 102.31, 102.15 (2*d*, C(1^{II}), C(1^{VIII})); 97.17, 96.82, 96.55, 96.52, 96.30 (5*d*, C(1^{III-VII})); 84.67 (*d*, C(3^{II})); 82.36 (*d*, C(2^{II})); 82.34 (*d*, C(3^{VII})); 81.18 (*d*, C(2^{VIII})); 81.56, 81.28, 81.24, 81.20 (4*d*, C(3^{III-VI})); 81.33 (*s*, C≡CH), 80.38 (*d*, C(3^{VIII})); 79.70, 79.58 (2 C), 79.42 (3*d*, C(2^{III-VI})); 78.48 (*d*, C(2^{VII})); 78.07 (*d*, C(5^I)); 78.15 (*s*, C(8^I)); 77.76 (*s*, C(7^I)); 76.19 (*d*, C(4^{VII})); 75.90, 75.02 (2*d*, C(3^I), C(4^{II})); 74.97 (*d*, C(5^{II})); 73.77 (*d*, C(2^I)); 73.50, 73.31, 72.75, 72.45 (4*d*, C(4^{III-VI})); 74.75–72.24 (several *t*, 24 ArCH₂); 72.01 (*s*, C≡CH); 71.21, 71.11, 70.93 (4 C), (3*d*, C(5^{III-VIII})); 70.03 (*t*, C(6^{VII})); 69.06 (2 C), 68.99, 68.82, 68.71 (4*t*, C(6^{II-VI})); 67.91 (*t*, C(1^I)); 67.47 (*t*, C(6^{VIII})); 66.61 (*d*, C(6^I)); 36.93 (*d*, C(4^{VIII})). HR-MALDI-MS: 4309.149 ($\text{C}_{220}\text{H}_{202}\text{Cl}_{23}\text{NaO}_{39}$), $[M + \text{Na}]^+$; calc: 4309.211). Anal. calc. for $\text{C}_{220}\text{H}_{203}\text{Cl}_{23}\text{O}_{39}$ (4286.41): C 61.65, H 4.77; found: C 61.75, H 4.88.*

6-*O-Acetyl-2,3-di-O-benzyl-α-D-glucopyranosyl-(1 → 4)-2,3,6-tri-O-benzyl-α-D-glucopyranosyl]_r-(1 → 3)-1,4,5-tri-O-benzyl-2,6-anhydro-7,8,9,10-tetradecy-D-glycero-L-gulo-deca-7,9-diynitol 10^I,4^{VIII}-Anhydride (**38**). A soln. of **32** (215 mg, 0.0624 mmol) in pyridine (40 ml) and MeCN (120 ml) was heated to 85°, treated with $\text{Cu}(\text{OAc})_2$ (570 mg, 3.12 mmol), refluxed for 3 h, and cooled to 23°. Evaporation and FC (silica H, toluene/AcOEt 40:1 → 30:1) gave **38** (107 mg, 50%). White foam. R_f (toluene/AcOEt 17:1) 0.28. M.p. 63–68°. $[\alpha]_D^{25} = +60.1$ ($c = 1.00$, CH_2Cl_2). IR (CH_2Cl_2): 3031m, 2925m, 2870m, 1741m, 1605m, 1496m, 1454m, 1362m, 1237m, 1209m, 1095s, 1028s, 910w. $^1\text{H-NMR}$ (500 MHz, CDCl_3 , assignment based on COSY spectra): 7.46–6.87 (*m*, 115 arom. H); 5.57 (*d*, $J = 3.8$), 5.47 (*d*, $J = 3.4$), 5.34 (*d*, $J = 3.7$), 5.30 (*d*, $J = 3.7$), 5.21 (*d*, $J = 3.6$), 5.19 (*d*, $J = 3.6$), 5.17 (*d*, $J = 3.4$) (H–C(1^{II-VIII})); 5.10 (*d*, $J = 11.1$, PhCH); 5.04 (*d*, $J = 11.0$, PhCH); 4.99 (*d*, $J = 10.8$, PhCH); 4.93–4.72 (*m*, 6 PhCH); 4.79 (*d*, $J = 10.6$, PhCH); 4.75 (*s*, 2 PhCH); 4.71–4.61 (*m*, 6 PhCH); 4.57 (*d*, $J = 10.8$, PhCH); 4.99–4.34 (*m*, 28 PhCH, H–C(6^I)); 4.18–4.10 (*m*, 2 H–C(6^{VIII})); 4.01–3.82 (*m*, 27 H); 3.81–3.71 (*m*, H–C(5), 2 H–C(6)); 3.67 (*dd*, $J = 6.0$, 9.1, H–C(5^I)); 3.58–3.41 (*m*, 13 H); 3.30 (*dd*, $J = 3.5$, 9.5, H–C(2)); 2.79 (*t*, $J = 10.6$, H–C(4^{VIII})); 1.97 (*s*, AcO). $^{13}\text{C-NMR}$ (125 MHz, CDCl_3 , assignment based on a HMQC spectrum): 170.96 (*s*, C=O); 139.30–137.66 (several *s*); 128.48–126.53 (several *d*); 98.26 (2 C), 98.21, 98.04, 97.86, 97.57, 97.42 (6*d*, C(1^{II-VIII})); 82.94 (*d*, C(4^I)); 81.17 (2 C), 81.06 (2 C), 80.93 (3 C) (3*d*, C(3^{II-VIII}));*

79.40 (2 C), 79.30, 79.17, 78.90, 78.85, 78.76, 78.48 (7d, C(5¹), C(2^{II-VIII})); 78.27 (s, C(8¹), C(9¹)); 77.51, 75.35 (2 C), 74.37 (2 C), 74.29 (2 C) (4d, C(3¹), C(4^{II-VIII})); 75.87, 68.28 (2s, C(7¹), C(10¹)); 75.12–72.77 (several t, 23 ArCH₂); 71.65, 71.57, 71.51, 71.35, 71.27, 71.94 (6d, C(2¹), C(5^{II-VIII})); 69.18, 69.00 (2 C), 68.93 (2 C), 68.80, 68.72 (5t, C(1¹), C(6^{II-VII})); 67.32 (d, C(6¹)); 64.18 (t, C(6^{VIII})); 37.69 (d, C(4^{VIII})); 20.79 (q, MeO). MALDI-MS: 3482 ([M + K]⁺), 3466 ([M + Na]⁺). Anal. calc. for C₂₁₅H₂₂₀O₄₀ (3444.12): C 74.98, H 6.44; found: C 74.65, H 6.73.

2,3,6-Tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl-[(1 \rightarrow 4)-2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-1,4,5-tris-O-(4-chlorobenzyl)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-deca-7,9-diynitol 10¹,4^{VIII}-Anhydride (**39**). A soln. of **34** (53 mg, 0.012 mmol) in pyridine (6.6 ml) and MeCN (20 ml) was heated to 85°, treated with Cu(OAc)₂ (11 mg, 0.062 mol), refluxed for 3 h, and cooled to 23°. Evaporation and FC (silica H, toluene/AcOEt 60 : 1 \rightarrow 30 : 1) gave **39** (31.7 mg, 60%). White foam. R_f (toluene/AcOEt 18 : 2) 0.56. [α]_D²⁵ = +62.0 (c = 1.00, CHCl₃). IR (CHCl₃): 2924m, 2869m, 1599m, 1491m, 1404m, 1358m, 1138s, 1090s, 1041s. ¹H-NMR (500 MHz, CDCl₃, assignment based on a HMQC-GRASP spectrum): 7.28–6.79 (m, 96 arom. H); 5.51 (d, J = 3.8), 5.46 (d, J = 3.5), 5.30 (d, J = 3.7), 5.15 (d, J = 3.5), 5.14 (d, J \approx 4.0), 5.12 (d, J \approx 4.0), 5.07 (d, J = 3.5) (H–C(1^{II-VIII})); 5.02 (d, J = 5.9, H–C(6¹)); 4.96 (d, J = 11.5), 4.89 (d, J = 11.3), 4.86 (d, J = 10.9), 4.85 (d, J = 11.8), 4.80 (d, J = 11.5), 4.77 (d, J = 11.5), 4.73 (d, J = 12.4), 4.71 (d, J = 10.8, 2 H), 4.66 (d, J = 11.6, 2 H) (11 ArCH); 4.55–4.50 (m, 6 ArCH); 4.45–4.26 (m, 31 ArCH); 3.95–3.68 (m, H–C(4¹), H–C(3^{II-VIII}), H–C(3¹), H–C(4^{II-VII}), H–C(2¹), H–C(5^{II-VIII}), 2 H–C(1¹), 4 H–C(6)); 3.65 (dd, J = 5.6, 9.1, H–C(5¹)); 3.56 (br. d, J = 10.2), 3.52 (br. d, J = 10.0), 3.49 (br. d, J = 10.5) (3 H–C(6)); 3.48–3.40 (m, H'–C(6^{II-VIII})); 3.41 (dd, J \approx 3.5, 9.1), 3.42 (dd, J \approx 3.5, 9.1), 3.39 (dd, J \approx 3.7, 8.8, 2 H), 3.34 (dd, J = 3.6, 9.1, 2 H), 3.33 (dd, J = 3.6, 9.1) (H–C(2^{II-VIII})); 3.36 (br. d, J \approx 11.8, H'–C(6^{VIII})); 2.95 (t, J = 10.6, H–C(4^{VIII})). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC-GRASP spectrum): 137.16–135.65 (several s); 134.13–132.48 (several s); 131.09–127.24 (several d); 98.33, 98.25, 98.19, 98.11, 98.06, 97.79, 97.41 (7d, C(1^{II-VIII})); 82.91 (d, C(4¹)); 81.01 (d, C(3^{VIII})); 80.72, 80.71 (3 C), 80.62, 80.61 (4d, C(3^{II-VII})); 79.69, 79.51, 79.40, 79.34, 78.93, 78.92, 78.90 (7d, C(2^{II-VIII})); 78.92 (d, C(5¹)); 78.52, 78.25, 78.09, 77.90, 77.02 (5d, C(4^{II-VI})); 77.89 (s, C(8¹), C(9¹)); 74.84, 74.37 (2d, C(3¹), C(4^{VIII})); 74.64–72.32 (several t, 24 ArCH₂); 73.42, 68.00 (2s, C(7¹), C(10¹)); 71.76, 71.67, 71.56, 71.46, 71.32, 71.15, 70.59 (7d, C(2¹), C(5^{II-VIII})); 69.28, 69.19, 69.09, 68.91 (2 C), 68.17 (3 C) (5t, C(1¹), C(6^{II-VIII})); 67.06 (d, C(6¹)); 37.49 (d, C(4^{VIII})). MALDI-MS: 4341 ([M + Na]⁺).

α -D-Glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-deca-7,9-diynitol 10¹,4^{VIII}-Anhydride (**40**). A soln. of **39** (111 mg, 0.026 mmol) in CH₂Cl₂ was treated with FeCl₃ (253 mg, 1.56 mmol) and stirred at 23° for 1.5 h. After the addition of H₂O (1 ml), the soln. was stirred at 23° for 5 min. Evaporation and FC (CH₂Cl₂/MeOH/H₂O 75/50/12) gave **40** (25 mg, 73%). White foam. R_f (CH₂Cl₂/MeOH/H₂O 75:50:12) 0.15. [α]_D²⁵ = +116.3 (c = 1.00, H₂O). ¹H-NMR (500 MHz, D₂O): 5.37 (br. s), 5.34 (d, J = 3.9), 5.24 (d, J = 4.0), 5.22 (d, J = 3.8), 5.17 (d, J = 3.3, 2 H), 4.91 (d, J = 3.6) (H–C(1^{II-VIII})); 4.89 (d, J = 6.0, H–C(6¹)); 4.14 (t, J = 8.1, 1 H); 3.97–3.72 (m, 29 H); 3.71–3.52 (m, 16 H); 3.39 (t, J = 9.4, 1 H); 2.71 (t, J = 10.5, H–C(4^{VIII})). ¹³C-NMR (125 MHz, D₂O): 103.90, 103.58, 103.47, 103.12, 102.74, 102.00, 101.93 (7d, C(1^{II-VIII})); 82.43, 81.59, 81.16, 80.86, 80.79, 79.99, 79.69 (7d, C(3¹), C(4^{II-VII})); 77.38–71.22 (several d, C(5¹), C(2^{II-VIII}), C(4¹), C(3^{II-VIII}), C(2¹), C(5^{II-VIII}), C(6¹)); 79.76, 76.37 (2s, C(7¹), C(10¹)); 71.61, 70.09 (2s, C(8¹), C(9¹)); 64.42, 63.25, 63.12, 63.06 (2 C), 62.88, 62.84, 62.79 (7t, C(1¹), C(6^{II-VIII})); 40.25 (d, C(4^{VIII})). HR-MALDI-MS: 1351.44 (C₅₂H₈₀NaO₃₉, [M + Na]⁺; calc. 1351.42).

6-O-Acetyl- α -D-glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-decitol 10¹,4^{VIII}-Anhydride (**41**). A suspension of **38** (120 mg, 0.0348 mmol) and 10% Pd(OH)₂/C (80 mg) in 2-methoxyethanol (10 ml) under H₂ (pressure 6 bar) was stirred at 23° for 48 h. The suspension was filtered over Celite, and the residue was washed with 2-methoxyethanol (2 ml), MeOH (2 ml), and H₂O (2 ml). After evaporation of the combined filtrate and washings, the residue was dissolved in H₂O (10 ml) and freeze-dried to give **41** (49.0 mg, 99%). White foam. M.p. 219° (dec.). ¹H-NMR (300 MHz, CD₃OD): 5.17 (d, J = 4.0, 2 H), 5.10 (d, J = 3.7), 5.09 (d, J = 4.0), 5.05 (d, J = 3.7, 2 H), 5.02 (d, J = 4.0) (H–C(1^{II-VIII})); 4.31 (br. d, J = 11.8, 2 H–C(6)); 4.15–4.01 (m, H–C(4^{VIII})); 4.00–3.38 (m, 47 H); 2.08 (s, AcO); 1.77–1.24 (m, (CH₂)₄). ¹³C-NMR (75 MHz, CD₃OD): 173.24 (s, C=O); 103.85 (6 C), 102.59 (2d, C(1^{II-VIII})); 82.72 (2 C), 82.35 (3 C), 81.91 (2 C) (3d, C(3¹), C(4^{II-VII})); 77.48, 76.14, 75.25 (5 C), 75.06 (5 C), 74.73 (3 C), 74.13 (3 C), 73.87 (3 C), 73.58 (2 C), 73.06 (9d, C(2¹), C(4¹), C(5¹), C(2^{II-VIII}), C(3^{II-VIII}), C(5^{II-VIII})); 66.07 (d, C(6¹)); 62.17 (7 C) (t, C(1¹), C(6^{II-VII})); 59.18 (t, C(6^{VIII})); 43.75 (d, C(4^{VIII})); 25.47 (t, 2 CH₂); 25.22 (t, 2 CH₂); 20.84 (q, OC(O)CH₃). MALDI-MS: 1403 ([M + Na]⁺).

α -D-Glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl]₆-(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-decitol 10¹,4^{VIII}-Anhydride (**42**). A soln. of **41** (49.0 mg, 0.0348 mmol) in MeOH/H₂O 1 : 1 (10 ml) was treated with 1M NaOMe (in 1 ml) and stirred at 23° for 20 h. The soln. was treated with Amberlite IR-120 (H⁺

form) and filtered. Evaporation, dissolution in H₂O (10 ml), and lyophilisation gave **42** (46.0 mg, 97%). White powder. M.p. 240° (dec.). ¹H-NMR (500 MHz, D₂O): 5.38 (*d*, *J* = 3.8), 5.28 (*d*, *J* = 3.8), 5.27 (*d*, *J* = 4.0), 5.20 (*d*, *J* = 3.8, 2 H), 5.19 (*d*, *J* = 3.9), 5.16 (*d*, *J* = 3.9) (H–C(1^{II-VIII})); 3.96–3.76 (*m*, 31 H); 3.72 (*dd*, *J* = 2.1, 7.8, 2 H); 3.69 (*dd*, *J* = 2.1, 7.8, 1 H); 3.67–3.54 (*m*, 15 H); 3.53 (*dd*, *J* = 3.9, 9.4, 1 H); 1.68–1.55, 1.37–1.32 (2*m*, H–C(4^{VIII}), (CH₂)₄). ¹H-NMR (300 MHz, (D₆)DMSO): 5.80–5.38 (*m*, HO–C(2^{II-VIII}), HO–C(4^I), HO–C(3^{II-VIII})); 5.00 (*d*, *J* = 3.9), 4.96 (*d*, *J* = 3.6), 4.93 (*d*, *J* = 3.6) (3 H–C(1)); 4.92–4.88 (*m*, 4 H, H–C(1), HO–C(5^I)); 4.87 (*d*, *J* = 3.4, H–C(1)); 4.71 (*d*, *J* = 4.8, HO–C(3^{VIII})); 4.58–4.42 (*m*, 8 H, HO–C(1^I), HO–C(6^{II-VIII})); 3.68–3.46 (*m*, 27 H); 3.37–3.20 (*m*, 21 H); 1.59–1.36 (*m*, 6 H), 1.30–1.18 (*m*, 3 H) (H–C(4^{VIII}), (CH₂)₄). ¹³C-NMR (125 MHz, D₂O): 103.81, 103.56, 103.52, 103.06, 103.01, 102.74, 102.47 (7*d*, C(1^{II-VIII})); 81.85, 81.80, 81.69, 81.12, 81.05, 80.79 (2 C) (6*d*, C(3^I), C(4^{II-VIII})); 77.98 (*d*, C(6^I)); 76.24–72.13 (several *d*, C(5^I), C(4^I), C(2^I), C(2^{II-VIII}), C(3^{II-VIII}), C(5^{II-VIII})); 64.13, 63.45, 63.12, 63.03 (2 C), 62.88 (2 C), 62.80 (6*t*, C(1^I), C(6^{II-VIII})); 44.07 (*d*, C(4^{VIII})); 27.90, 27.76, 27.67, 26.16 (4*t*, 4 CH₂). MALDI-MS: 1360 ([*M* + Na]⁺). Anal. calc. for C₅₂H₈₈O₃₉ · 7 H₂O (1462.35): C 42.68, H 7.02 found: C 42.76, H 6.75.

6-*O*-Acetyl-2,3-di-*O*-benzyl-β-D-glucopyranosyl-[(1 → 4)-2,3,6-tri-*O*-benzyl-α-D-glucopyranosyl]₅-(1 → 3)-1,4,5-tri-*O*-benzyl-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-deca-7,9-diyntol 10^I,4^{VIII}-Anhydride (**43**). A soln. of **33** (99.2 mg, 0.0287 mmol) in pyridine (15 ml) and MeCN (45 ml) was heated to 85°, treated with Cu(OAc)₂ (26.1 mg, 0.144 mmol), refluxed for 3 h, and cooled to 23°. Evaporation and FC (silica H, toluene/AcOEt 40:1 → 30:1) gave **43** (59.3 mg, 60%). White foam. *R*_f (toluene/AcOEt 17:1) 0.37. M.p. 61–65°. [*α*]_D²⁵ = +49.8 (*c* = 0.75, CH₂Cl₂). IR (CH₂Cl₂): 3030*m*, 2925*m*, 1741*m*, 1605*m*, 1496*m*, 1454*m*, 1362*m*, 1094*s*, 1028*s*, 826*w*. ¹H-NMR (500 MHz, CDCl₃, assignment based on COSY spectra): 7.46–7.00 (*m*, 115 arom. H); 5.56 (*d*, *J* = 3.6), 5.37 (*d*, *J* = 3.7), 5.35 (*d*, *J* = 3.8), 5.28 (*d*, *J* = 3.4), 5.24 (*t*, *J* ≈ 4.4, 2 H) (H–C(1^{II-VIII})); 5.05 (*d*, *J* = 11.1, ArCH); 4.99 (*d*, *J* = 11.0, 2 ArCH); 4.93 (*d*, *J* = 11.1, ArCH); 4.87 (*d*, *J* = 10.8, ArCH); 4.86 (*d*, *J* = 10.6, 2 ArCH); 4.82–4.28 (*m*, 39 ArCH, H–C(6^I), H–C(1^{VIII})); 4.16 (*t*, *J* = 8.2, 1 H); 4.42–4.01 (*m*, 3 H); 4.00–3.87 (*m*, 23 H); 3.83–3.80 (*m*, 1 H); 3.52–3.41 (*m*, 16 H); 3.40–3.30 (*m*, 2 H); 3.21 (*t*, *J* = 7.0, H–C(4)); 2.74 (*t*, *J* = 10.3, H–C(4^{VIII})); 1.95 (*s*, AcO). ¹³C-NMR (125 MHz, CDCl₃, assignment based on a HMQC spectrum): 170.28 (*s*, C=O); 139.25–137.78 (several *s*); 128.44–126.54 (several *d*); 99.53 (*d*, C(1^{VIII})); 98.17, 98.06, 98.00, 97.63, 97.37, 96.83 (6*d*, C(1^{II-VIII})); 82.54 (*d*, C(4^I)); 81.95 (*d*, C(2^{VIII})); 81.47, 81.39, 81.15 (2 C), 80.98 (2 C) (6*d*, C(3^{II-VIII})); 80.93, 79.99 (2*s*, C(8^I), C(9^I)); 79.63, 79.50, 79.03, 78.83, 78.71, 78.19, 78.00 (7*d*, C(5^I), C(2^{II-VIII})); 77.75 (*s*, C(7^I), C(10^I)); 75.44–72.90 (several *t*, 23 ArCH₂); 74.87 (4 C), 74.41 (2 C), 73.85 (2 C) (3*d*, C(4^I), C(3^{II-VIII})); 72.70, 72.93, 71.47, 71.43, 71.35, 71.18, 71.10, 70.93 (8*d*, C(2^I), C(5^{II-VIII})); 69.12 (2 C), 69.04, 68.85, 68.74 (2 C), 68.44 (5*t*, C(1^I), C(6^{II-VIII})); 67.31 (*d*, C(6^I)); 64.57 (*t*, C(6^{VIII})); 37.22 (*d*, C(4^{VIII})); 20.86 (*q*, Me). MALDI-MS: 3483 ([*M* + K]⁺), 3466 ([*M* + Na]⁺). Anal. calc. for C₂₁₅H₂₂₀O₄₀ (3444.09): C 74.98, H 6.44; found: C 74.89, H 6.86.

2,3,6-Tris-*O*-(4-chlorobenzyl)-β-D-glucopyranosyl-[(1 → 4)-2,3,6-tris-*O*-(4-chlorobenzyl)-α-D-glucopyranosyl]₅-(1 → 3)-1,4,5-tris-*O*-(4-chlorobenzyl)-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-deca-7,9-diyntol 10^I,4^{VIII}-Anhydride (**44**). A soln. of **35** (177 mg, 0.041 mmol) in pyridine (22 ml) and MeCN (66 ml) was heated to 85°, treated with Cu(OAc)₂ (60 mg, 0.33 mmol), refluxed for 3 h, and cooled to 23°. Evaporation and FC (silica H, toluene/AcOEt 60:1 → 30:1) gave **44** (105 mg, 56%). White foam. *R*_f (toluene/AcOEt 18:2) 0.53. [*α*]_D²⁵ = +61.6 (*c* = 1.00, CHCl₃). IR (CHCl₃): 2926*m*, 2868*m*, 1724*m*, 1599*m*, 1492*s*, 1408*m*, 1359*m*, 1261*m*, 1090*s*, 1039*s*, 1016*s*. ¹H-NMR (500 MHz, CDCl₃): 7.91–6.80 (*m*, 96 arom. H); 5.31 (*d*, *J* = 3.4), 5.21 (*d*, *J* = 3.3), 5.20 (*d*, *J* = 3.0), 5.19 (*d*, *J* = 3.0, 2 H), 5.14 (*d*, *J* = 3.4) (H–C(1^{II-VIII})); 4.97 (*d*, *J* = 11.7, ArCH); 4.89 (*d*, *J* = 6.0, H–C(6^I)); 4.77 (*d*, *J* = 11.4), 4.75 (*d*, *J* = 11.6), 4.76 (*d*, *J* = 11.6), 4.72 (*d*, *J* = 11.3) (4 ArCH); 4.71 (*d*, *J* ≈ 7.5, H–C(1^{VIII})); 4.70 (*d*, *J* ≈ 11.0), 4.67 (*d*, *J* = 11.3), 4.63 (*d*, *J* = 11.3), 4.61 (*d*, *J* = 11.7), 4.58 (*d*, *J* ≈ 11.0, 3 H), 3.61 (*d*, *J* = 11.7), 4.58 (*d*, *J* = 11.0), 4.54 (*d*, *J* = 11.7), 4.51 (*d*, *J* = 11.4, 2 H), 4.46 (*d*, *J* = 11.8, 2 H), 4.43 (*d*, *J* = 13.1, 2 H), 4.40 (*d*, *J* = 13.2, 2 H) (20 ArCH); 4.37–4.28 (*m*, 23 ArCH); 4.03–3.97 (*m*, H–C(3^I), H–C(2^I), H–C(1^I), 2 ArCH); 3.93–3.73 (*m*, H–C(4^I), H–C(3^{II-VIII}), H–C(4^{II-VIII}), H–C(5^{II-VIII}), 5 H–C(6)); 3.66–3.58 (*m*, H–C(5^I), H⁺–C(1^I), H–C(6)); 3.54–3.34 (*m*, H–C(2^{II-VIII}), H–C(3^{VIII}), H⁺–C(6^{II-VIII})); 3.32–3.24 (*m*, H–C(5^{VIII})); 3.16 (*t*, *J* = 7.3, H–C(2^{VIII})); 2.82 (*t*, *J* = 10.4, H–C(4^{VIII})). ¹³C-NMR (125 MHz, CDCl₃): 137.34–135.78 (several *s*); 134.01–132.99 (several *s*); 130.88–127.36 (several *d*); 99.55 (*d*, C(1^{VIII})); 98.47, 98.36, 98.15, 97.94, 97.85, 97.27 (6*d*, C(1^{II-VIII})); 82.36 (*d*, C(4^I)); 81.58 (*d*, C(2^{VIII})); 81.42 (*d*, C(3^{VIII})); 80.87, 80.71 (2 C), 80.62 (2 C), 80.44 (4*d*, C(3^{II-VIII})); 70.39 (3 C), 79.25 (3 C) (2*d*, C(2^{II-VIII})); 78.77 (*d*, C(4^{VI})); 78.36 (*d*, C(5^I)); 77.74 (2*s*, C(7^I), C(10^I)); 78.10, 77.89, 77.59 (2 C), 75.51, 74.62 (5*d*, C(3^I), C(4^{II-VIII})); 73.26, 68.18 (2*s*, C(8^I), C(9^I)); 74.62–72.23 (several *t*, 24 ArCH₂); 71.70 (2 C), 71.49, 71.40 (2 C), 71.15, 70.91 (5*d*, C(2^I), C(5^{II-VIII})); 70.39, 69.30 (2 C), 69.04 (2 C), 68.95 (2 C), 68.28 (5*t*, C(1^I), C(6^{II-VIII})); 67.19 (*d*, C(6^I)); 37.20 (*d*, C(4^{VIII})). MALDI-MS: 4340 ([*M* + Na]⁺). Anal. calc. for C₂₂₀H₂₀₀Cl₂₄O₃₉ (4318.84): C 61.18, H 4.67, Cl 19.70; found: C 61.34, H 4.93, Cl 19.54.

β -D-Glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl] $_{6-}$ -(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-deca-7,9-diyntol 10^l,4^{viii}-Anhydride (**45**). A soln. of **44** (100 mg, 0.023 mmol) in CH₂Cl₂ was treated with FeCl₃ (228 mg, 1.40 mmol) and stirred at 23° for 1.5 h. After the addition of H₂O (1 ml), the soln. was stirred at 23° for 5 min. Evaporation and FC (CH₂Cl₂/MeOH/H₂O 75:50:12) gave **45** (26 mg, 75%). White foam. *R*_f (CH₂Cl₂/MeOH/H₂O 75:50:12) 0.16. [α]_D²⁵ = +90.7 (*c* = 1.00, H₂O). ¹H-NMR (300 MHz, D₂O): 5.36 (br. *s*); 5.32 (*d*, *J* ≈ 4.2), 5.30 (*d*, *J* ≈ 4.8), 5.27 (br. *s*), 5.22 (*d*, *J* = 3.3), 5.18 (*d*, *J* = 3.3) (H-C(1^{iv-vii})); 4.85 (*d*, *J* = 5.7, H-C(6^l)); 4.46 (*d*, *J* = 8.4, H-C(1^{viii})); 4.07 (*t*, *J* ≈ 9.0, 1 H); 4.04–3.72 (*m*, 24 H); 3.69–3.53 (*m*, 20 H); 3.37 (*t*, *J* = 9.0, 1 H); 3.20 (*t*, *J* = 8.4, 1 H); 2.71 (*t*, *J* = 10.2, H-C(4^{viii})). ¹³C-NMR (75 MHz, D₂O): 104.07 (*d*, C(1^{viii})); 103.55, 103.21, 102.69, 101.85, 101.33, 101.20 (6*d*, C(1^{ii-vii})); 81.35, 80.90, 80.31, 79.62, 79.44, 79.28, 79.09 (7 *d*, C(3^l), C(4^{ii-vii})); 78.16–71.33 (several *d*, C(2^l), C(3^l), C(5^l), C(6^l), C(2^{ii-viii}), C(3^{ii-viii}), C(5^{ii-viii})); 79.97, 76.67 (2*s*, C(7^l), C(10^l)); 72.53, 70.61 (2*s*, C(8^l), C(9^l)); 64.81, 63.27, 63.45 (2 *C*), 63.31, 63.20 (3 *C*) (5*t*, C(1^l), C(6^{ii-viii})); 40.59 (*d*, C(4^{viii})). HR-MALDI-MS: 1351.44 (C₅₂H₈₆NaO₃₉, [M + Na]⁺, calc: 1351.42).

6-O-Acetyl- β -D-glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl] $_{6-}$ -(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-decitol 10^l,4^{viii}-Anhydride (**46**). A suspension of **37** (90.0 mg, 0.0261 mmol) and 10% Pd(OH)₂/C (70 mg) in 2-methoxyethanol (10 ml) was stirred at 23° under H₂ (6 bar) for 48 h. The suspension was filtered over *Celite* and the residue washed with 2-methoxyethanol (2 ml), MeOH (2 ml), and H₂O (2 ml). Evaporation, dissolution in H₂O (10 ml), and lyophilisation gave **46** (32.2 mg, 89%). White foam. M.p. 225° (dec.). ¹H-NMR (300 MHz, CD₃OD): 5.20 (*d*, *J* = 4.0), 5.17 (*d*, *J* = 4.0), 5.09 (*d*, *J* = 3.7), 5.07 (*d*, *J* = 4.0), 5.04 (*d*, *J* = 3.7), 5.02 (*d*, *J* = 3.7) (H-C(1^{ii-vii})); 4.40 (br. *t*, *J* ≈ 10.6, 2 H); 4.02 (br. *dd*, *J* = 7.8, 11.8, 2 H); 3.98–3.12 (*m*, 46 H); 2.11 (*s*, AcO); 1.24–1.70 (*m*, (CH₂)₄). ¹³C-NMR (75 MHz, CD₃OD): 173.20 (*s*, C=O); 104.50 (*d*, C(1^{viii})); 104.00, 103.77 (2 *C*), 103.38, 103.10, 102.55 (5*d*, C(1^{ii-vii})); 82.90, 82.56 (2 *C*), 82.25 (2 *C*), 81.77, 81.59 (5*d*, C(3^l), C(4^{ii-vii})); 77.01, 76.77 (3 *C*), 76.12, 75.25 (5 *C*), 74.97 (2 *C*), 74.70 (4 *C*), 74.24 (2 *C*), 74.10 (2 *C*), 73.84 (2 *C*), 73.47, 73.19 (11*d*, C(2^l), C(4^l), C(5^l), C(2^{ii-viii}), C(3^{ii-viii}), C(5^{ii-viii})); 66.02 (*d*, C(6^l)); 63.18, 62.38 (2 *C*), 62.18 (4 *C*) (3*t*, C(1^l), C(6^{ii-vii})); 59.20 (*t*, C(6^{viii})); 43.75 (*d*, C(4^{viii})); 28.18 (br. *t*, 2 CH₂); 26.31, 25.71 (2*t*, 2 CH₂); 20.97 (*q*, Me). MALDI-MS: 1420 ([M + K]⁺), 1404 ([M + Na]⁺).

β -D-Glucopyranosyl-[(1 \rightarrow 4)- α -D-glucopyranosyl] $_{6-}$ -(1 \rightarrow 3)-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-decitol 10^l,4^{viii}-Anhydride (**47**). A soln. of **46** (32.2 mg, 0.0232 mmol) in MeOH/H₂O 1:1 (10 ml) was treated with 1*M* NaOMe in MeOH (1 ml) and stirred at 23° for 20 h. The soln. was treated with *Amberlite IR-120* (H⁺ form) and filtered. Evaporation, dissolution in H₂O (10 ml), and lyophilisation gave **47** (31.2 mg, 99%). White powder. M.p. 221° (dec.). ¹H-NMR (500 MHz, D₂O, assignment based on a HMQC spectrum): 5.34 (*d*, *J* = 4.2), 5.30 (*d*, *J* = 4.2), 5.25 (*d*, *J* = 3.7), 5.22 (*d*, *J* = 4.1), 5.20 (*d*, *J* = 3.8), 5.16 (*d*, *J* = 3.6) (H-C(1^{ii-vii})); 4.52 (*d*, *J* = 7.9, H-C(1^{viii})); 4.01–3.98 (*m*, H-C(6^l)); 3.99 (*t*, *J* = 9.0, H-C(3)); 3.95–3.77 (*m*, 25 H); 3.74 (*dd*, *J* = 5.7, 13.2, 1 H); 3.72–3.71 (*m*, 2 H); 3.66–3.58 (*m*, 14 H); 3.55 (*t*, *J* = 9.0, H-C(4)); 3.49 (br. *t*, *J* ≈ 9.6, H-C(5^{viii})); 3.40 (*t*, *J* = 10.0, H-C(3^{viii})); 3.22 (*dd*, *J* = 8.0, 9.1, H-C(2^{viii})); 1.78–1.72 (*m*, 1 H, CH₂); 1.55–1.49 (*m*, 4 H, CH₂); 1.43–1.40 (*m*, 2 H, H-C(4^{viii}), CH₂); 1.32–1.28 (*m*, 2 H, CH₂). ¹H-NMR (500 MHz, DMSO, assignment based on a COSY spectrum): 5.77–5.75 (*m*, 3 H, HO-C(2), HO-C(3)); 5.73 (*d*, *J* = 6.8, HO-C(2)); 5.68 (*d*, *J* = 2.8, HO-C(3)); 5.60 (*d*, *J* = 7.3, HO-C(2)); 5.58 (*d*, *J* = 3.1, HO-C(3)); 5.54 (*d*, *J* = 8.2, HO-C(2)); 5.53 (*d*, *J* = 2.8, HO-C(3)); 5.47 (*d*, *J* = 7.1, HO-C(2)); 5.46 (*d*, *J* = 6.5, HO-C(2)); 5.38 (*d*, *J* = 2.7, HO-C(3)); 5.06 (*d*, *J* = 4.6, HO-C(2^{viii})); 5.03 (*d*, *J* = 3.9), 5.00 (*d*, *J* = 3.9), 4.96 (*d*, *J* = 3.6, 2 H), 4.94 (*d*, *J* = 3.9), 4.89 (*d*, *J* = 3.5) (H-C(1^{ii-vii})); 4.97 (*d*, *J* ≈ 2.6, HO-C(3^{viii})); 4.92 (*d*, *J* = 5.0, HO-C(5^l)); 4.78 (*d*, *J* = 5.8, HO-C(3^{viii})); 4.77 (*t*, *J* = 4.8, HO-C(6^{viii})); 4.57 (*t*, *J* = 5.3), 4.53–4.43 (*m*, 5 H), 4.40 (*t*, *J* = 5.9) (HO-C(6^{ii-vii}), HO-C(1^l)); 4.25 (*d*, *J* = 7.4, H-C(1^{viii})); 3.61–3.45 (*m*, 27 H); 3.40–3.25 (*m*, 24 H); 3.20 (br. *t*, *J* ≈ 9.1, H-C(5^{viii})); 3.09–3.04 (*m*, H-C(3^{viii})); 2.95–2.91 (*m*, H-C(2^{viii})); 1.54–1.49 (*m*, 1 H, CH₂); 1.48–1.38 (*m*, 4 H, CH₂); 1.29–1.25 (*m*, 2 H, H-C(4^{viii}), CH₂); 1.18–1.09 (*m*, 2 H, CH₂). ¹³C-NMR (125 MHz, D₂O, assignment based on a HMQC spectrum): 104.85 (*d*, C(1^{viii})); 103.98, 103.27, 103.05, 102.95, 102.89, 102.72 (6*d*, C(1^{ii-vii})); 82.54, 82.49, 81.79, 81.26, 81.23, 81.17, 80.81 (7*d*, C(3^l), C(4^{ii-vii})); 79.96 (*d*, C(5^{viii})); 78.09 (*d*, C(6^l)); 77.65 (*d*, C(3^{viii})); 77.48 (*d*, C(2^{viii})); 76.66, 76.27, 76.07, 75.83, 75.67, 75.53, 75.29 (7*d*, C(4^l), C(3^{ii-vii})); 75.04, 74.89, 74.73, 74.56, 74.47 (3 *C*), 74.26, 74.15, 74.03 (3 *C*), 73.92, 73.85 (10*d*, C(5^l), C(2^{ii-vii}), C(2^l), C(5^{ii-vii})); 63.46, 63.97, 63.27, 63.10, 63.05 (2 *C*), 62.88 (2 *C*) (6*t*, C(1^l), C(6^{ii-viii})); 44.57 (*d*, C(4^{viii})); 29.21, 28.97, 26.58, 26.51 (4*t*, 4 CH₂). MALDI-MS: 1360 ([M + Na]⁺). Anal. calc. for C₅₂H₈₆O₃₉ (1327.24): C 42.68, H 7.02; found: C 42.83, H 6.70.

2,3,6-Tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl-(1 \rightarrow 4)-6-O-benzyl-2,3-bis-O-(4-chlorobenzyl)- α -D-glucopyranosyl-[(1 \rightarrow 4)-2,3,6-tris-O-(4-chlorobenzyl)- α -D-glucopyranosyl] $_{4-}$ -(1 \rightarrow 4)-2,3,6-tris-O-(4-chlorobenzyl)- β -D-glucopyranosyl-(1 \rightarrow 3)-1,4,5-tris-O-(4-chlorobenzyl)-2,6-anhydro-7,8,9,10-tetra-deoxy-D-glycero-L-gulo-deca-7,9-diyntol 10^l,4^{viii}-Anhydride (**48**). A soln. of **36** (200 mg, 0.046 mmol) in pyridine (25 ml) and MeCN (75 ml) was heated to 85°, treated with Cu(OAc)₂ (42 mg, 0.23 mmol), refluxed for 5 h, and cooled to 23°. After

evaporation, a soln. of the residue in Et₂O (60 ml) was washed with an aq. soln. of (TMEDA)Na₄ (140 µl, 0.93 mmol), H₂O (50 ml), and brine (50 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 50:1 → 20:1) gave **48** (80 mg, 40%). White foam. *R*_f (toluene/AcOEt 9:1) 0.55. $[\alpha]_D^{25} = +49.5$ (*c* = 1.00, CHCl₃). IR (CHCl₃): 2927*m*, 2869*m*, 1599*m*, 1492*s*, 1408*m*, 1359*m*, 1138*m*, 1090*s*, 1040*s*, 1016*s*. ¹H-NMR (400 MHz, CDCl₃): 7.30–6.87 (*m*, 97 arom. H); 5.49 (*d*, *J* = 3.5), 5.47 (*d*, *J* = 3.7), 5.39 (*d*, *J* = 3.4), 5.15 (*d*, *J* = 3.5), 5.12 (*t*, *J* = 4.1, 2 H) (H–C(1^{III-VIII})); 4.94 (*d*, *J* = 11.2), 4.93 (*d* = 11.5) (2 ArCH); 4.91 (*d*, *J* = 6.5, H–C(6^I)); 4.86 (*d*, *J* = 11.2), 4.85 (*d*, *J* = 12.1), 4.84 (*d*, *J* = 11.5), 4.78 (*d*, *J* = 11.2), 4.73 (*d*, *J* ≈ 11.0), 4.72 (*d*, *J* ≈ 11.0) (6 ArCH); 4.67–4.22 (*m*, 40 ArCH, H–C(1^{II})); 4.03 (*dt*, *J* = 3.4, 9.7, 1 H); 4.00–3.73 (*m*, 22 H); 3.70–3.53 (*m*, 9 H); 3.49–3.37 (*m*, 12 H); 3.31 (*t*, *J* = 8.1, H–C(2^{II})); 3.28 (*dd*, *J* = 3.6, 6.0, 1 H); 3.25 (*td*, *J* = 3.2, 9.6, H–C(5^{II})); 2.95 (*t*, *J* = 10.5, H–C(4^{VIII})). ¹³C-NMR (100 MHz, CDCl₃): 137.85–135.46 (several *s*); 134.12–133.01 (several *s*); 129.41–127.45 (several *d*); 101.48 (*d*, C(1^{II})); 98.69, 98.48, 98.30, 97.84, 96.77, 95.25 (*6d*, C(1^{III-VIII})); 84.94 (*d*, C(3^{II})); 82.24 (*d*, C(2^{II})); 81.59, 80.79 (2 C), 80.49 (2 C), 80.23, 79.80, 79.62, 79.34, 78.84, 78.73, 77.58 (2 C), 77.22 (3 C), 76.26, 76.21, 70.21, 75.54, 74.09, 73.75 (2 C) (17*d*, C(3^I), C(4^I), C(5^I), C(4^{II-VIII}), C(2^{II-VIII}), C(3^{II-VIII})); 81.31, 77.97 (2*s*, C(7^I), C(10^I)); 74.70–72.06 (several *t*, 24 ArCH₂); 71.93, 68.00 (2*s*, C(8^I), C(9^I)); 71.72 (4 C), 71.31, 70.81, 70.67, 70.19 (5*d*, C(2^I), C(5^{II-VIII})); 70.31, 69.59, 69.07 (3 C), 68.89 (2 C), 68.11 (5*t*, C(1^I), C(6^{II-VIII})); 66.56 (*d*, C(6^I)); 37.59 (*d*, C(4^{VIII})). MALDI-MS: 4306 ([*M* + Na]⁺), 4324 ([*M* + K]⁺).

α-D-Glucopyranosyl-[(1 → 4)-*α*-D-glucopyranosyl]₅-(1 → 4)-β-D-glucopyranosyl-(1 → 3)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-deca-7,9-diyntitol 10^I,4^{VIII}-Anhydride (**49**). A soln. of **48** (95 mg, 0.022 mmol) in CH₂Cl₂ was treated with FeCl₃ (210 mg, 1.29 mmol) and stirred at 23° for 1.5 h. After the addition of H₂O (1 ml), the soln. was stirred at 23° for 5 min. Evaporation and FC (CH₂Cl₂/MeOH/H₂O 75:50:12) gave **49** (23 mg, 78%). White foam. *R*_f (CH₂Cl₂/MeOH/H₂O 75:50:12) 0.13. ¹H-NMR (300 MHz, D₂O): 5.71 (*d*, *J* = 3.6), 5.42 (*d*, *J* = 3.9), 5.40 (*d*, *J* ≈ 4.2), 5.34 (*d*, *J* = 3.6), 5.23 (*d*, *J* = 3.9), 5.20 (*d*, *J* = 3.9) (H–C(1^{III-VIII})); 4.92 (*d*, *J* = 7.8, H–C(1^{II})); 4.87 (*d*, *J* = 6.3, H–C(6^I)); 4.09 (*t*, *J* = 9.6, 1 H); 4.04–3.78 (*m*, 25 H); 3.74–3.53 (*m*, 20 H); 3.32 (*t*, *J* = 9.0, 1 H); 2.74 (*t*, *J* = 10.2, H–C(4^{VIII})). HR-MALDI-MS: 1351.44 (C₅₂H₈₀NaO₃₉, [*M* + Na]⁺; calc: 1351.42).

2,3,6-Tris-O-(4-chlorobenzyl)-β-D-glucopyranosyl-(1 → 4)-6-O-benzyl-2,3-bis-O-(4-chlorobenzyl)-*α*-D-glucopyranosyl-[(1 → 4)-2,3,6-tris-O-(4-chlorobenzyl)-*α*-D-glucopyranosyl]₄-(1 → 4)-2,3,6-tris-O-(4-chlorobenzyl)-β-D-glucopyranosyl-(1 → 3)-1,4,5-tris-O-(4-chlorobenzyl)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-deca-7,9-diyntitol 10^I,4^{VIII}-Anhydride (**50**). A soln. of **37** (320 mg, 0.07 mmol) in pyridine (39 ml) and MeCN (118 ml) was heated to 85°, treated with Cu(OAc)₂ (68 mg, 0.37 mmol), refluxed for 5 h, and cooled to 23°. After evaporation, a soln. of the residue in Et₂O (80 ml), was washed with an aq. soln. of (TMEDA)Na₄ (223 µl, 1.5 mmol), H₂O (50 ml), and brine (50 ml), and dried (MgSO₄). Evaporation and FC (toluene/AcOEt 50:1 → 20:1) gave **50** (146 mg, 45%). White foam. *R*_f (toluene/AcOEt 9:1) 0.70. $[\alpha]_D^{25} = 47.4$ (*c* = 1.00, CHCl₃). IR (CHCl₃): 2926*m*, 2869*m*, 1599*m*, 1492*s*, 1408*m*, 1359*m*, 1261*m*, 1090*s*, 1040*s*, 1016*s*. ¹H-NMR (400 MHz, CDCl₃): 7.91–6.80 (*m*, 96 arom. H); 5.31 (*d*, *J* = 3.4), 5.21 (*d*, *J* = 3.3), 5.20 (*d*, *J* = 3.0), 5.19 (*d*, *J* ≈ 3.0), 5.14 (*d*, *J* = 3.4) (H–C(1^{III-VIII})); 4.97 (*d*, *J* = 11.7, ArCH); 4.89 (*d*, *J* = 6.0, H–C(6^I)); 4.77 (*d*, *J* = 11.4), 4.75 (*d*, *J* = 11.6, 2 H), 4.72 (*d*, *J* = 11.3), 4.70 (*d*, *J* = 10.3, 2 H), 4.67 (*d*, *J* = 11.3), 4.63 (*d*, *J* = 11.3), 4.61 (*d*, *J* = 11.7), 4.58 (*d*, *J* ≈ 11.0, 3 H), 3.61 (*d*, *J* = 11.7), 4.58 (*d*, *J* = 11.0, 2 H), 4.54 (*d*, *J* = 11.7), 4.51 (*d*, *J* = 11.4, 2 H), 4.46 (*d*, *J* = 11.8, 2 H), 4.43 (*d*, *J* = 13.1, 2 H), 4.40 (*d*, *J* = 13.2, 2 H) (24 ArCH); 4.37–4.28 (*m*, 24 ArCH, H–C(1^{II}), H–C(1^{VIII})); 4.15 (*ddd*, *J* = 2.0, 3.5, 9.8, H–C(5)); 4.09 (*t*, *J* = 8.9, 1 H); 4.01–3.97 (*m*, 2 H); 4.93–3.81 (*m*, 16 H); 3.74 (*t*, *J* = 8.6, 1 H); 3.70–3.63 (*m*, 6 H); 3.60 (*dd*, *J* = 4.0, 10.7, 1 H); 3.54–3.32 (*m*, 16 H); 3.28 (*dd*, *J* = 7.2, 8.5, H–C(2)); 3.21 (*dd*, *J* ≈ 1.5, 3.5, 9.5, H–C(5^{II})); 3.05 (*dd*, *J* ≈ 7.5, 8.2, 1 H); 2.82 (*t*, *J* = 10.4, H–C(4^{VIII})). ¹³C-NMR (100 MHz, CDCl₃): 137.82–135.46 (several *s*); 134.98–132.90 (several *s*); 129.58–127.42 (several *d*); 100.39 (*d*, C(1^{II}), C(1^{VIII})); 98.61, 98.29, 97.81, 97.00, 96.50 (5*d*, C(1^{III-VIII})); 84.43 (*d*, C(3^{II})); 82.49 (*d*, C(2^{II})); 81.99, 81.62, 81.30, 80.70, 80.65, 80.58, 80.17, 79.91, 79.56, 79.47, 79.36, 79.04, 78.69, 78.41 (2 C), 77.52, 77.24 (2 C), 75.98, 75.84, 74.45, 74.10, 73.76 (23*d*, C(3^I), C(4^{II-VIII}), C(5^I), C(2^{II-VIII}), C(4^I), C(3^{II-VIII})); 77.90 (*s*, C(7^I), C(10^I)); 74.03–72.21 (several *t*, 24 ArCH₂); 72.74, 71.73, 71.53, 71.45, 71.40, 71.18 (6*d*, C(5^{II-VIII})); 70.40, 69.32 (2 C), 69.13 (3 C), 68.90, 68.65 (5*t*, C(1^I), C(6^{II-VIII})); 72.94, 68.44 (2*s*, C(8^I), C(9^I)); 66.57 (*d*, C(6^I)); 37.40 (*d*, C(4^{VIII})). MALDI-MS: 4305 ([*M* + Na]⁺), 4324 ([*M* + K]⁺).

β-D-Glucopyranosyl-[(1 → 4)-*α*-D-glucopyranosyl]₅-(1 → 4)-β-D-glucopyranosyl-(1 → 3)-2,6-anhydro-7,8,9,10-tetraoxy-D-glycero-L-gulo-deca-7,9-diyntitol 10^I,4^{VIII}-Anhydride (**51**). A soln. of **50** (59 mg, 13.7 µmol) in CH₂Cl₂ was treated with FeCl₃ (134 mg, 0.826 mmol) and stirred at 23° for 1.5 h. After the addition of H₂O (1 ml), the soln. was stirred at 23° for 5 min. Evaporation and FC (CH₂Cl₂/MeOH/H₂O 75:50:12) gave **51** (13 mg, 71%). White foam. *R*_f (CH₂Cl₂/MeOH/H₂O 75:50:12) 0.15. ¹H-NMR (500 MHz, D₂O): 5.47 (*d*, *J* = 4.2), 5.30 (*d*, *J* = 4.0), 5.22 (*d*, *J* = 4.0), 5.15 (*d*, *J* = 3.6), 5.08 (*d*, *J* = 3.6) (H–C(1^{III-VIII})); 4.88 (*d*, *J* = 5.4,

H–C(6^l); 4.79 (*d*, *J* = 7.7), 4.70 (*d*, *J* = 7.8) (H–C(1^{ll}), H–C(1^{viii})); 4.20 (*ddd*, *J* = 2.1, 5.1, 10.2, H–C(5)); 4.08 (*t*, *J* = 9.4, 1 H); 3.99 (*t*, *J* = 9.2, 1 H); 3.95–3.55 (*m*, 43 H); 3.40 (*t*, *J* = 9.5, 1 H); 2.72 (*t*, *J* = 10.4, H–C(4^{viii})). ¹³C-NMR (125 MHz, D₂O): 104.12, 103.89 (*d*, C(1^{ll}), C(1^{viii})); 103.61, 102.90, 102.39, 102.01, 100.80 (5*d*, C(1^{ll-viii})); 83.24, 81.96, 81.92, 80.54, 80.47, 78.81, 78.36, 78.29, 77.54, 77.38, 77.33, 77.04, 76.56, 76.45, 76.26, 76.14, 75.98, 75.73, 75.56, 74.79, 74.49 (2 C), 74.39, 74.30, 74.20 (4 C), 74.07 (2 C), 73.82, 72.49, 71.06 (2*8d*, C(3^l), C(4^{ll-vii}), C(5^l), C(2^{ll-viii}), C(4^l), C(3^{ll-viii}), C(2^l), C(5^{ll-viii}), C(6^l)); 64.60, 63.52, 63.21 (2 C), 63.12 (2 C), 63.00, 62.93 (6*t*, C(1^l), C(6^{ll-viii})); 40.62 (*d*, C(4^{viii})). HR-MALDI-MS: 1351.44 (C₅₂H₈₀NaO₃₉, [M + Na]⁺; calc: 1351.42).

REFERENCES

- [1] K. V. S. N. Murty, A. Vasella, *Helv. Chim. Acta* **2001**, *84*, 939.
- [2] A. G. Meyers, C. J. Easton, S. F. Lincoln, G. W. Simpson, *J. Org. Chem.* **1998**, *63*, 9069; R. L. VanEtten, J. F. Sebastian, G. A. Clowes, M. L. Bender, *J. Am. Chem. Soc.* **1967**, *89*, 3242; R. L. VanEtten, G. A. Clowes, J. F. Sebastian, M. L. Bender, *J. Am. Chem. Soc.* **1967**, *89*, 3253; M. Komiyama, M. L. Bender, *J. Am. Chem. Soc.* **1978**, *100*, 4576; O. S. Tee, B. K. Takasaki, *Can. J. Chem.* **1985**, *63*, 3540; O. S. Tee, C. Mazza, X. Du, *J. Org. Chem.* **1990**, *55*, 3603; I. Tabushi, *Acc. Chem. Res.* **1982**, *15*, 66; R. Breslow, in 'Inclusion Compounds', Eds. J. L. Atwood, J. E. D. Davies and D. D. MacNicol, Academic Press, London, 1984, Vol. 3, p. 485; V. T. D'Souza, M. L. Bender, *Acc. Chem. Res.* **1987**, *20*, 146; R. Breslow, *Acc. Chem. Res.* **1995**, *28*, 146; C. J. Easton, S. Kassara, S. F. Lincoln, B. L. May, *Aust. J. Chem.* **1995**, *48*, 269; R. Breslow, C. Schmuck, *J. Am. Chem. Soc.* **1996**, *118*, 6601; B. Zhang, R. Breslow, *J. Am. Chem. Soc.* **1997**, *117*, 1676; R. Breslow, H. Kohn, B. Siegel, *Tetrahedron Lett.* **1976**, 1645; M. Komiyama, H. Hirai, *J. Am. Chem. Soc.* **1984**, *106*, 174; H. Ye, D. Rong, V. T. D'Souza, *Tetrahedron Lett.* **1991**, *32*, 5231; H. Ye, W. Tong, V. T. D'Souza, *J. Am. Chem. Soc.* **1992**, *114*, 5470.
- [3] W. H. Chen, S. Hayashi, T. Tahara, Y. Nogami, T. Koga, M. Yamaguchi, K. Fujita, *Chem. Pharm. Bull.* **1999**, *47*, 588.
- [4] J. Szejtli, in 'Inclusion Compounds', Eds. J. L. Atwood, J. E. D. Davies and D. D. MacNicol, Academic Press, London, 1984, Vol. 3, p. 349; J. Szejtli, 'Cyclodextrin Technology', Kluwer Academic Publishers, Dordrecht, 1988; D. Duchêne, 'New Trends in Cyclodextrins and Derivatives', Editions de Santé, Paris, 1991; D. Duchêne, *J. Coord. Chem.* **1992**, *27*, 223; K. Uekama, F. Hirayama, T. Irie, in 'New Trends in Cyclodextrins and Derivatives', Ed. D. Duchêne, Editions de Santé, Paris, France, 1991, Chapt. 12; R. Breslow, S. D. Dong, *Chem. Rev.* **1998**, *98*, 1997; B. Pfannemüller, W. Burchard, *Makromol. Chem.* **1969**, *1*, 121.
- [5] J. Szejtli, 'Cyclodextrins and their Inclusion Complexes', Academiai Kiado, Budapest, 1982; G. Wenz, *Angew. Chem.* **1994**, *106*, 851.
- [6] E. Rizzarelli, G. Vecchio, *Coord. Chem. Rev.* **1999**, *188*, 343.
- [7] M. L. Hilton, D. W. Armstrong, in 'New Trends in Cyclodextrins and Derivatives', Ed. D. Duchêne, Edition de Santé, Paris, France, 1991, Chapt. 15.
- [8] M. T. Rojas, R. Koniger, J. F. Stoddart, A. E. Kaifer, *J. Am. Chem. Soc.* **1995**, *117*, 336; M. Lahav, K. T. Ranjit, E. Katz, I. Willner, *Chem. Commun.* **1997**, 3259; K. Odashima, M. Kotato, M. Sugawara, Y. Umezawa, *Anal. Chem.* **1993**, *65*, 927.
- [9] K. A. Connors, *Chem. Rev.* **1997**, *97*, 1325; M. V. Rekharsky, Y. Inoue, *Chem. Rev.* **1998**, *98*, 1875; T. Andersson, K. Nilsson, M. Sundahl, G. Westman, O. Wennerström, *J. Chem. Soc., Chem. Commun.* **1992**, 604; C. Lu, C. Hu, Y. Yu, Q. Meng, *Chem. Pharm. Bull.* **2000**, *48*, 56; T. Hladon, J. Pawlaczky, B. Szafran, *J. Inclusion Phenom. Macrocycl. Chem.* **1999**, *35*, 497; B. Golankiewicz, G. Perlovich, J. Poznanski, L. Stefaniak, J. Zeidler, W. Zielenkiewicz, *J. Chem. Soc., Perkin Trans. 2* **1999**, 2533; G. Shixiang, W. Liansheng, H. Qingguo, H. Sukui, *Chemosphere* **1998**, *37*, 1299; W. Saenger, *Angew. Chem., Int. Ed.* **1980**, *19*, 344; Y. Kuroda, Y. Suzuki, J. He, T. Kawabata, A. Shibukawa, H. Wada, H. Fujima, Y. Go-oh, E. Imai, T. Nakagawa, *J. Chem. Soc., Perkin Trans. 2* **1995**, 1749; A. Botsi, K. Yannakopoulou, E. Hadjoudis, J. Waite, *Carbohydr. Res.* **1996**, *283*, 1; H. Ohvo, J. P. Slotte, *Biochemistry* **1996**, *35*, 8108; T. Andersson, M. Sundahl, G. Westman, O. Wennerström, *Tetrahedron Lett.* **1994**, *35*, 7103; J. Szejtli, *J. Mater. Chem.* **1997**, *7*, 575.
- [10] M. L. Bender, M. Komiyama, 'Cyclodextrin Chemistry', Springer-Verlag, Berlin, 1978; R. I. Gelb, L. M. Schwartz, B. Cardelino, F. H. S., R. F. Johnson, D. A. Laufer, *J. Am. Chem. Soc.* **1981**, *103*, 1750; R. I. Gelb, L. M. Schwartz, D. A. Laufer, *J. Chem. Soc., Perkin Trans. 2* **1984**, 15; F. W. Lichtenthaler, S. Immel, *Tetrahedron: Asymmetry* **1994**, *5*, 2045.
- [11] 'Comprehensive Supramolecular Chemistry', Vol. 3, Elsevier Science Ltd., Oxford, 1996.

- [12] P. Bortolus, G. Marconi, S. Monti, B. Mayer, G. Köhler, G. Grabner, *Chem. Eur. J.* **2000**, *6*, 1578.
- [13] Z. Yi, H. Chen, Z. Huang, Q. Huang, J. Yu, *J. Chem. Soc., Perkin Trans. 2* **2000**, 121.
- [14] T. Steiner, W. Saenger, *Angew. Chem.* **1998**, *110*, 3628; A. Ueno, R. Breslow, *Tetrahedron Lett.* **1982**, *23*, 3451; S. Tian, P. Forgo, V. T. D'Souza, *Tetrahedron Lett.* **1996**, *37*, 8309; D. Rong, V. T. D'Souza, *Tetrahedron Lett.* **1990**, *30*, 4275; K. A. Martin, M. A. Mortellaro, R. W. Sweger, L. E. Fikers, D. T. Winn, S. Clary, W. P. Johnson, A. W. Czarnik, *J. Am. Chem. Soc.* **1995**, *117*, 10443; A. R. Khan, P. Forgo, K. J. Stine, V. T. D'Souza, *Chem. Rev.* **1998**, *98*, 1977; P. S. Bansal, C. L. Francis, N. K. Hart, S. A. Henderson, D. Oakenfull, A. D. Robertson, G. W. Simpson, *Aust. J. Chem.* **1998**, *51*, 915.
- [15] K. Koga, K. Ishida, T. Yamada, D.-Q. Yuan, K. Fujita, *Tetrahedron Lett.* **1999**, *40*, 923; I. Tabushi, K. Shimokawa, N. Shimizu, H. Shirakata, K. Kujita, *J. Am. Chem. Soc.* **1976**, *98*, 7855; I. Tabushi, K. Fujita, L. C. Yuan, *Tetrahedron Lett.* **1977**, 2503; A. Ueno, H. Yoshimura, R. Saka, T. Osa, *J. Am. Chem. Soc.* **1979**, *101*, 2779; A. Ueno, Y. Takahashi, T. Osa, *J. Chem. Soc., Chem. Commun.* **1981**, 94; I. Tabushi, Y. Kuroda, K. Yokota, L. C. Yuan, *J. Am. Chem. Soc.* **1981**, *103*, 711; I. Tabushi, L. Yua, *J. Am. Chem. Soc.* **1981**, *103*, 3574; I. Tabushi, H. Yamamura, T. Nabeshima, *J. Am. Chem. Soc.* **1984**, *106*, 5267; I. Tabushi, T. Nabeshima, K. Fujita, A. Matsunaga, T. Imoto, *J. Org. Chem.* **1985**, *50*, 2638; T. Kato, Y. Nakamura, *Heterocycles* **1988**, *27*, 973; R. Breslow, J. W. Canary, M. Varney, S. T. Waddell, D. Yang, *J. Am. Chem. Soc.* **1990**, *112*, 5212; A. M. Aquino, C. J. Albert, K. L. Berger, C. M. Darragh, S. E. Kelley, M. V. Cossette, *J. Am. Chem. Soc.* **1990**, *112*, 5819; G. Yi, J. S. Bradshaw, B. E. Rossiter, S. L. Rees, P. Petersson, K. E. Markides, M. L. Lee, *J. Org. Chem.* **1993**, *58*, 2561; R. P. Bonomo, G. Impellizzeri, G. Pappalardo, E. Rizzarelli, G. Vecchio, *Gazz. Chim. Ital.* **1993**, *123*, 593; K. Pikramenou, K. M. Johnson, D. G. Nocera, *Tetrahedron Lett.* **1993**, 3531; M. F. Acquavella, M. E. Evans, S. W. Farraher, C. J. Nevoret, C. J. Abelt, *J. Chem. Soc., Perkin Trans. 2* **1995**, 385; D. Yuan, K. Koga, M. Yamaguchi, K. Fujita, *Chem. Commun.* **1996**, 1943; D. Yuan, K. Koga, K. Fujita, M. Yamaguchi, *Tetrahedron Lett.* **1997**, 7593.
- [16] J. Szejtli, T. Osa, in 'Cyclodextrins', Eds. J. L. Atwood, J. E. D. Davies, D. D. MacNicol and F. Vögtle, Pergamon Press, Budapest, 1996; K. Fujita, W.-H. Chen, D.-Q. Yuan, Y. Nogami, T. Koga, T. Fujioka, K. Mihashi, S. Immel, F. W. Lichtenthaler, *Tetrahedron: Asymmetry* **1999**, *10*, 1689; Y. Nogami, K. Nasu, T. Koga, K. Ohta, K. Fujita, S. Immel, H. J. Lindner, G. E. Schmitt, F. W. Lichtenthaler, *Angew. Chem.* **1997**, *109*, 1987; S.-H. Chiu, D. C. Myles, *J. Org. Chem.* **1999**, *64*, 332; S. Tian, H. Zhu, P. Forgo, V. T. D'Souza, *J. Org. Chem.* **2000**, *65*, 2624; K. Harata, *J. Chem. Soc., Perkin Trans. 2* **1994**, 271; M. R. Cairra, V. Griffith, L. R. Nassimberri, B. van Oudtshoorn, *J. Chem. Soc., Perkin Trans. 2* **1994**, 2071.
- [17] R. R. Bukownik, C. S. Wilcox, *J. Org. Chem.* **1988**, *53*, 463; S. Penadés, J. M. Coterón, *J. Chem. Soc., Chem. Commun.* **1992**, 683; J. M. Coterón, C. Vicent, C. Bosso, S. Penadés, *J. Am. Chem. Soc.* **1993**, *115*, 10066; Y. Wang, J. Mao, M. Cai, *Synth. Commun.* **1999**, *29*, 2093.
- [18] J. A. Haselgrave, J. F. Stoddart, D. J. Thompson, *Tetrahedron Lett.* **1979**, 2279; P. P. Kanakamma, N. S. Mani, V. Nair, *Synth. Commun.* **1995**, *25*, 3777; P. P. Kanakamma, N. S. Mani, U. Maitra, V. Nair, *J. Chem. Soc., Perkin Trans. 1* **1995**, 2339; B. Dumont, J.-P. Joly, Y. Chapleur, *Bioorg. Med. Chem. Lett.* **1994**, *4*, 1123; R. Ellinghaus, G. Schröder, *Liebigs Ann. Chem.* **1985**, 418; H. Gruber, G. Schröder, *Liebigs Ann. Chem.* **1985**, 421.
- [19] R. Bürli, Ph. D. Thesis, ETH-Zürich, Nr. 12404, 1997.
- [20] R. Bürli, A. Vasella, *Helv. Chim. Acta* **1997**, *80*, 1027; R. Bürli, A. Vasella, *Helv. Chim. Acta* **1997**, *80*, 2215; R. Bürli, A. Vasella, *Angew. Chem., Int. Ed.* **1997**, *36*, 1852.
- [21] R. Bürli, A. Vasella, *Helv. Chim. Acta* **1999**, *82*, 485.
- [22] W. Saenger, *Israel. J. Chem.* **1985**, *25*, 43; W. Saenger, 'Hydrogen Bonding in Biological Structures', Springer-Verlag, Berlin, 1991.
- [23] N. Sakairi, L.-X. Wang, H. Kuzuhara, *J. Chem. Soc., Perkin Trans. 1* **1995**, 437.
- [24] R. Bürli, A. Vasella, *Helv. Chim. Acta* **1996**, *79*, 1159.
- [25] A. Ernst, A. Vasella, *Helv. Chim. Acta* **1996**, *79*, 1279.
- [26] M. P. LaMontagne, A. Markovac, J. R. Menke, *J. Med. Chem.* **1977**, *20*, 1122.
- [27] W. Brade, Ph. D. Thesis, Universität Zürich, 1990.
- [28] A. Ernst, Ph. D. Thesis, ETH-Zürich, Nr. 12858, 1998.
- [29] W. A. Szarek, A. Zamojski, K. N. Tiwari, E. R. Ison, *Tetrahedron Lett.* **1986**, *27*, 3827.
- [30] A. Veyrières, *J. Chem. Soc., Perkin Trans. 1* **1981**, 1626.
- [31] R. Roy, F. D. Tropper, S. Cao, J. M. Kim, in 'ACS Symposium Series', Ed. M. E. Halpern, ACS, Washington, 1997, Vol. 659, p. 163.
- [32] C. Cai, Ph. D. Thesis, ETH-Zürich, Nr. 11725, 1996; C. Cai, A. Vasella, *Helv. Chim. Acta* **1995**, *78*, 732; C. Cai, A. Vasella, *Helv. Chim. Acta* **1995**, *78*, 2053; C. Cai, A. Vasella, *Helv. Chim. Acta* **1996**, *79*, 255; T. V.

- Bohner, Ph. D. Thesis, ETH-Zürich, Nr. 13133, 1999; T. V. Bohner, O.-S. Becker, A. Vasella, *Helv. Chim. Acta* **1999**, 82, 198; T. V. Bohner, R. Beaudegnies, A. Vasella, *Helv. Chim. Acta* **1999**, 82, 143.
- [33] F. Cramer, G. Mackensen, K. Senses, *Chem. Ber.* **1969**, 102, 494.
- [34] S. Hanessian, Y. Guindon, *Carbohydr. Res.* **1980**, 86, C3.
- [35] P. J. Garegg, C.-G. Swahn, *Methods Carbohydr. Chem.* **1980**, VIII, 317.
- [36] M. E. Evans, *Carbohydr. Res.* **1972**, 21, 473.
- [37] M. Ek, P. J. Garegg, H. Hultberg, S. Oscarson, *J. Carbohydr. Chem.* **1983**, 2, 305.
- [38] S. D. Debenham, E. J. Toone, *Tetrahedron: Asymmetry* **2000**, 11, 385.
- [39] M. J. Cloninger, H. W. Whitlock, *J. Org. Chem.* **1998**, 63, 6153.
- [40] B. Bernet, A. Vasella, *Helv. Chim. Acta* **2000**, 83, 2055.
- [41] F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, C. Caufield, M. Lipton, G. Chang, T. Hendrickson, W. C. Still, *J. Comput. Chem.* **1990**, 11, 440.
- [42] T. D. W. Claridge, 'High-Resolution NMR Techniques in Organic Chemistry', Elsevier Science, Oxford, 1999, p. 142.

Received June 5, 2001